

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 14/00, 14/705, C12N 5/16, 15/12, 15/63, G01N 33/53, 33/566	A1	(11) International Publication Number: WO 99/31129 (43) International Publication Date: 24 June 1999 (24.06.99)
(21) International Application Number: PCT/US98/26364 (22) International Filing Date: 11 December 1998 (11.12.98) (30) Priority Data: 60/069,401 12 December 1997 (12.12.97) US 60/104,251 14 October 1998 (14.10.98) US (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): CHEN, Fang [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: DNA MOLECULES ENCODING HUMAN NUCLEAR RECEPTOR PROTEINS, nNR7 AND nNR7-1 (57) Abstract The present invention discloses the isolation and characterization of cDNA molecules encoding a novel member to the human nuclear receptor superfamily, designated nNR7 and/or nNR7-1. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of nNR7 and/or nNR7-1 activity, and production of antibodies against nNR7 and/or nNR7-1, or epitopes thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION
DNA MOLECULES ENCODING HUMAN NUCLEAR
RECEPTOR PROTEINS, nNR7 and nNR7-1

5

CROSS-REFERENCE TO RELATED APPLICATIONS

Provisional application 60/104,251 filed October 14, 1998,
which is a continuation of Provisional application 60/069,401 filed
December 12, 1997.

10

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not applicable.

15

REFERENCE TO MICROFICHE APPENDIX

Not applicable.

20

FIELD OF THE INVENTION

The present invention relates in part to isolated nucleic acid
molecules (polynucleotide) which encodes a human nuclear receptor
proteins, referred to throughout as nNR7 and nNR7-1, respectively. The
present invention also relates to recombinant vectors and recombinant
25 hosts which contain a DNA fragment encoding nNR7 and nNR7-1,
substantially purified forms of associated human nNR7 protein and
associated human nNR7-1 protein, human mutant proteins of nNR7
and nNR7-1, and methods associated with identifying compounds which
modulate nNR7 and nNR7-1 activity.

30

BACKGROUND OF THE INVENTION

The nuclear receptor superfamily, which includes steroid hormone receptors, are small chemical ligand-inducible transcription factors which have been shown to play roles in controlling development, differentiation and physiological function. Isolation of cDNA clones encoding nuclear receptors reveal several characteristics. First, the NH₂-terminal regions, which vary in length between receptors, is hypervariable with low homology between family members. There are three internal regions of conservation, referred to as domain I, II and III. Region I is a cysteine-rich region which is referred to as the DNA binding domain (DBD). Regions II and III are within the COOH-terminal region of the protein and is also referred to as the ligand binding domain (LBD). For a review, see Power et al. (1992, *Trends in Pharmaceutical Sciences* 13: 318-323).

The lipophilic hormones that activate steroid receptors are known to be associated with human diseases. Therefore, the respective nuclear receptors have been identified as possible targets for therapeutic intervention. For a review of the mechanism of action of various steroid hormone receptors, see Tsai and O'Malley (1994, *Annu. Rev. Biochem.* 63: 451-486).

Recent work with non-steroid nuclear receptors has also shown the potential as drug targets for therapeutic intervention. This work reports that peroxisome proliferator activated receptor γ (PPAR γ), identified by a conserved DBD region, promotes adipocyte differentiation upon activation and that thiazolidinediones, a class of antidiabetic drugs, function through PPAR γ (Tontonoz et al., 1994, *Cell* 79: 1147-1156; Lehmann et al., 1995, *J. Biol. Chem.* 270(22): 12953-12956; Teboul et al., 1995, *J. Biol. Chem.* 270(47): 28183-28187). This indicates that PPAR γ plays a role in glucose homeostasis and lipid metabolism.

Baes et al. (1994, *Mol. Cell. Biol.* 14(3):1544-1552) disclose a cDNA clone which encodes a new member of the nuclear receptor superfamily, referred herein as hONX. The authors present data showing that the gene is expressed mainly in human liver and suggests that this nuclear receptor may play a role in regulating expression of retinoid-responsive genes.

Baker, et al. (1988, *Proc. Natl. Acad. Sci. (U.S.A.)* 85 (10): 3294-3298) disclose a cDNA clone which encodes human vitamin D receptor (hVDR).

5 Mangelsdorf et al. (1995, *Cell* 83: 835-839) provide a review of known members of the nuclear receptor superfamily, including hONX and hVDR.

It would be advantageous to identify additional genes which are members of the nuclear receptor superfamily, especially vertebrate members from such species as human, rat and mouse. A nucleic acid
10 molecule expressing a nuclear receptor protein will be useful in screening for compounds acting as a modulator of cell differentiation, cell development and physiological function. The present invention addresses and meets these needs by disclosing isolated nucleic acid molecules which express a human nuclear receptor protein which will
15 have a role in cell differentiation and development.

SUMMARY OF THE INVENTION

The present invention relates to isolated nucleic acid molecules (polynucleotides) which encode novel nuclear receptor
20 proteins which are herein designated as members of the nuclear receptor superfamily. The isolated polynucleotides of the present invention encode vertebrate members of this nuclear receptor superfamily, and preferably human nuclear receptor proteins, such as human nuclear receptor proteins exemplified and referred to
25 throughout this specification as nNR7 and/or nNR7-1. The nuclear receptor proteins encoded by the isolated polynucleotides of the present invention are involved in the regulation of *in vivo* cell proliferation and/or cell development. Based on amino acid sequence homology, the nuclear receptor that is most related to human nNR7 and/or nNR7-1
30 with known function is the vitamin D receptor. Northern analysis on the following human tissue samples -- heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, adrenal medulla, thyroid, adrenal cortex, testis, thymus, small intestine and stomach -- reveals that nNR7 and/or nNR7-1 is expressed mainly in liver at medium to low
35 level and the small intestine. It may be expressed at much higher level in other tissues not examined. This data suggest that nNR7 and/or

nNR7-1 plays important roles in carrying out metabolic functions involving D vitamins, since the liver is the major site for generation of hydroxylated D vitamins, which are active forms of vitamin D for the vitamin D receptor. It is also possible that other vitamin D metabolites
5 may be active forms for nNR7 and/or nNR7-1 in the liver.

As noted above, nNR7 and/or nNR7-1 and are expressed in the liver and small intestine. In humans, the cytochrome P-450 monooxygenase 3A4 (CYP3A4) is mainly expressed in the liver and small intestine. The CYP3A4 protein plays an important role in the
10 biotransformation of drugs, including more than 60% of all clinically used drugs, and its expression level is markedly induced by those compounds. Therefore, assays that measure the effects of compounds on CYP3A4 gene expression can predict whether drugs will interact in humans. Because the molecular mechanism underlying this induction
15 is unclear, CYP3A4 gene induction assays have been almost exclusively dependent upon the use of human liver tissue and primary hepatocytes to date. The nNR7 and/or nNR7-1 nuclear receptor disclosed in this application has been disclosed by Lehmann et al. (1998, *J. Clin. Invest* 102: 1016-1023) subsequent to the priority filing date of this specification.
20 The authors identified a response element located in the CYP3A4 promoter [5'-TGAAGT ccaagg AGGTCA-3' (SEQ ID NO:24)] that was shown to bind nNR7 (referred to as hPXR by the authors, but lacking in amino acid 1-32 of nNR7 [SEQ ID NO:2]). The authors suggest that drugs which induce CYP3A4 gene expression activate nNR7 and initiate
25 transcription through CYP3A4 promoter. One of the uses of the DNA molecules and concomitantly expressed proteins of the present invention, including but not limited to nNR7 and nNR7-1, will be useful in assays to identify modulators of CYP3A4 levels *in vivo*. Therefore, transactivation assays using nNR7 and/or nNR7-1 and the CYP3A4
30 promoter linked to a reporter gene (such as SEAP -- secreted placental alkaline phosphatase) is one approach for identifying modulators of CYP3A4 levels *in vivo*.

The present invention also relates to isolated nucleic acid fragments which encode mRNA expressing a biologically active novel
35 vertebrate nuclear receptor which belongs to the nuclear receptor superfamily.

A preferred embodiment relates to isolated nucleic acid fragments of SEQ ID NO: 1 and/or SEQ ID NO:17 which encode mRNA expressing a biologically functional derivative of nNR7 and/or nNR7-1, respectively. Any such nucleic acid fragment will encode either a
5 protein or protein fragment comprising at least an intracellular DNA-binding domain and/or ligand binding domain, domains conserved throughout the human nuclear receptor family domain which exist in nNR7 (SEQ ID NO: 2) and/or nNR7-1 (SEQ ID NO:18). Any such
10 polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists of nNR7 and/or nNR7-1.

15 The isolated nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic
20 acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).

The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout
25 this specification.

A preferred aspect of the present invention is disclosed in Figure 1A-C and SEQ ID NO: 1, an isolated human cDNA encoding a novel nuclear trans-acting receptor protein, nNR7.

30 An especially preferred aspect of the present invention is disclosed in Figure 4A-C and SEQ ID NO: 17, an isolated human cDNA encoding a novel nuclear trans-acting receptor protein, nNR7-1.

Another preferred aspect of the present invention relates to a substantially purified form of the novel nuclear trans-acting receptor protein, nNR7, which is disclosed in Figure 2A-C and Figure 3 and as
35 set forth in SEQ ID NO: 2.

Another especially preferred aspect of the present invention relates to a substantially purified form of the novel nuclear trans-acting receptor protein, nNR7-1, which is disclosed in Figure 5A-C and Figure 6 and is set forth as SEQ ID NO: 18. The receptor protein nNR7-1
5 contains an amino terminal addition compared to nNR7; specifically wherein nNR7-1 contains an initiating methionine residue as the NH₂-terminal amino acid residue.

The present invention also relates to biologically functional derivatives of nNR7 as set forth as SEQ ID NO: 2, including but not
10 limited to nNR7 mutants and biologically active fragments such as amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations, such that these fragments provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and would be useful for screening for
15 agonists and/or antagonists of nNR7 function.

The present invention also relates to polyclonal and monoclonal antibodies raised in response to either the human form of nNR7 and/or nNR7-1 disclosed herein, or a biologically functional derivative thereof. It will be especially preferable to raise antibodies
20 against epitopes within the NH₂-terminal domain of nNR7 and/or nNR7-1, which show the least homology to other known proteins belonging to the human nuclear receptor superfamily. To this end, the DNA molecules, RNA molecules, recombinant protein and antibodies of the present invention may be used to screen and measure levels of
25 human nNR7 and/or nNR7-1. The recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of human nNR7 and/or nNR7-1.

The present invention also relates to isolated nucleic acid
30 molecules which are fusion constructions expressing fusion proteins useful in assays to identify compounds which modulate wild-type human nNR7 and/or nNR7-1 activity. A preferred aspect of this portion of the invention includes, but is not limited to, glutathione S-transferase GST-nNR7 and/or GST-nNR7-1 fusion constructs. These fusion
35 constructs include, but are not limited to, all or a portion of the ligand-binding domain of nNR7 and/or nNR7-1, respectively, as an in-frame

fusion at the carboxy terminus of the GST gene. The disclosure of SEQ ID NOs:1, 2, 17 and 18 allow the artisan of ordinary skill to construct any such nucleic acid molecule encoding a GST-nuclear receptor fusion protein. Soluble recombinant GST-nuclear receptor fusion proteins may
5 be expressed in various expression systems, including *Spodoptera frugiperda* (SF21) insect cells (Invitrogen) using a baculovirus expression vector (e.g., Bac-N-Blue DNA from Invitrogen or pAcG2T from Pharmingen). Another preferred aspect of this portion of the invention relates to the use of a receptor/reporter system to identify
10 modulators of nNR7, nNR7-1 and/or CYP3A4 levels *in vivo*. As an example, and not as a limitation, the portion of SEQ ID NO:1 or SEQ ID NO:17 which encodes the open reading frame of nNR7 and nNR7-1, respectively, may be fused downstream of an active promoter, such as a CMV promoter fragment, so as to overexpress a receptor protein. A
15 second construct includes regulatory regions from the human CYP3A4 gene (such as the human CYP3A4 promoter region or a response element [e.g., SEQ ID NO:24]) fused to a reporter gene, such as SEAP (secreted placental alkaline phosphatase). These constructs may then be utilized in a transactivation assay to identify modulators of CYP3A4
20 levels *in vivo*.

It is an object of the present invention to provide an isolated nucleic acid molecule which encodes a novel form of a nuclear receptor protein such as human nNR7 and/or nNR7-1, human nuclear receptor protein fragments of full length proteins such as nNR7 and/or nNR7-1,
25 and mutants which are derivatives of SEQ ID NO: 2 and/or SEQ ID NO:18, respectively. Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein
30 fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for nNR7 and/or nNR7-1 function.

Another object of this invention is tissue typing using probes or antibodies of this invention. In a particular embodiment,
35 polynucleotide probes are used to identify tissues expressing nNR7 and/or nNR7-1 mRNA. In another embodiment, probes or antibodies

can be used to identify a type of tissue based on nNR7 and/or nNR7-1 expression or display of nNR7 and/or nNR7-1 receptors.

It is a further object of the present invention to provide the human nuclear receptor proteins or protein fragments encoded by the nucleic acid molecules referred to in the preceding paragraph.

It is a further object of the present invention to provide recombinant vectors and recombinant host cells which comprise a nucleic acid sequence encoding human nNR7 and/or nNR7-1 or a biological equivalent thereof.

It is an object of the present invention to provide a substantially purified form of nNR7 and/or nNR7-1, as set forth in SEQ ID NO: 2 and SEQ ID NO:18, respectively.

It is an object of the present invention to provide for biologically functional derivatives of nNR7 and/or nNR7-1, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these fragment and/or mutants provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.

It is also an object of the present invention to provide for in-frame fusion constructions of nNR7 and/or nNR7-1 and the like, methods of expressing these fusion constructions and biological equivalents disclosed herein, related assays, recombinant cells expressing these constructs and agonistic and/or antagonistic compounds identified through the use DNA molecules encoding human nuclear receptor proteins such as nNR7 and/or nNR7-1.

As used herein, "DBD" refers to DNA binding domain.

As used herein, "LBD" refers to ligand binding domain.

As used herein, the term "mammalian host" refers to any mammal, including a human being.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-C shows the nucleotide sequence which comprises the open reading frame encoding the human nuclear receptor protein, nNR7 (SEQ ID NO: 1).

Figure 2A-C shows the nucleotide sequence of the isolated cDNA molecule (SEQ ID NO: 1) which encodes nNR7, and the amino

acid sequence of (SEQ ID NO: 2) nNR7. The region in bold and underline is the DNA binding domain.

Figure 3 shows the amino acid sequence of nNR7 (SEQ ID NO: 3). The region in bold and underline is the DNA binding domain.

5 Figure 4A-C shows the nucleotide sequence which comprises the open reading frame encoding the human nuclear receptor protein, nNR7 (SEQ ID NO: 1). The region of nucleotides which are underlined represent the extended 5'-end of the nNR7 cDNA clone (as shown in SEQ ID NO:1 and Figure 1A-C).

10 Figure 5A-C shows the nucleotide sequence of the isolated cDNA molecule (SEQ ID NO: 17) which encodes nNR7-1, and the amino acid sequence of (SEQ ID NO:18) nNR7-1. The region of nucleotides which are underlined represent the extended 5'-end of the nNR7 cDNA clone (as shown in SEQ ID NO:1 and Figure 1A-C). The amino acid
15 region underlined represents the DNA binding domain.

Figure 6 shows the amino acid sequence of nNR7-1 (SEQ ID NO: 18). The region in bold is the DNA binding domain. The underline indicates the extended N-terminus of nNR7-1 as compared to nNR7.

20 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to isolated nucleic acid and protein forms which represent nuclear receptors, preferably but not necessarily limited to human receptors. These expressed proteins are novel nuclear receptors and which are useful in the identification of
25 downstream target genes and ligands regulating their activity. The nuclear receptor proteins encoded by the isolated polynucleotides of the present invention are involved in the regulation of *in vivo* cell proliferation and/or cell development. The nuclear receptor superfamily is composed of a group of structurally related receptors which are
30 regulated by chemically distinct ligands. The common structure for a nuclear receptor is a highly conserved DNA binding domain (DBD) located in the center of the peptide and the ligand-binding domain (LBD) at the COOH-terminus. Eight out of the nine non-variant cysteines form two type II zinc fingers which distinguish nuclear receptors from other
35 DNA-binding proteins. The DBDs share at least 50% to 60% amino acid sequence identity even among the most distant members in vertebrates.

The superfamily has been expanded within the past decade to contain approximately 25 subfamilies. A first exemplified cDNA encoding human nNR was identified via low stringency screening on a mixed cDNA library. The probes used in the screening were DNA fragments corresponding to AR, ERb, GR and VDR DNA binding domain regions and 250,000 primary clones from the mixed library were screened. After two rounds of screening, *in vivo* excision was carried out on the purified lZAPII phages which showed positive signals at low stringency condition. Plasmid DNA samples were submitted to sequence directly using M13 forward and reverse primers. A blast search of the sequence information was obtained using computer program PhredPhrap. A single cDNA clone, referred to as gm6, is shown herein to encode a novel human nuclear receptor, nNR7. DNA sequencing was continued from both 5' and 3' ends on nNR7. An intron was identified when sequencing with pgm6y2 (5'-CTTCAATGTCATGACATG-3'; SEQ ID NO: 3). A cDNA fragment flanking the intron region was retrieved via PCR using primer pair of NR7F (5'-CCAAATCTGCCGTGTATGTG-3'; SEQ ID NO: 4) and pgm6xC (5'-GTCAGTGCACTCTCCACGT-3'; SEQ ID NO: 5) followed by double nested primers of pgm6y2 and pgm6xD (5'-TGCAGCTGGTCCACCACGCG-3'; SEQ ID NO: 6). A prominent DNA fragment of ~1.5 kb was amplified from testis and brain cDNAs. The fragment was purified and subcloned into pCRII vector (Invitrogen, San Diego, CA). Automated sequencing was performed on several of the clones. The complete sequencing of gm6 clone revealed a 3.1 kb cDNA which codes an authentic novel nuclear receptor. The open reading frame for the expressed protein does not contain an initiating methionine.

Primer pair pgm6xAR (5'-GGGTATGCTCTGTGACAAG-3'; SEQ ID NO: 7) and pgm6x (5'-AGGCAGGCACTTTCATACC-3'; SEQ ID NO: 8) in 3' non-coding region were used to scan the 83 clones of the Stanford radiation hybrid panel (Cox et al., 1990, *Science*, 250:245:250). The PCR results were scored and submitted to the Stanford Genome Center for linkage analysis. The result indicated that nNR7 was located on chromosome 3. Northern analysis on Clontech blots showed that nNR7 was mainly expressed in human liver at medium to low level. The nNR7 polypeptide has a 42% sequence identity at the amino acid

level with human VDR (Baker, et al., 1988, *Proc. Natl. Acad. Sci. (U.S.A.)* 85 (10): 3294-3298) in the overlapping regions. Additionally, the nNR7 polypeptide has a 52% sequence identity at the amino acid level with human hONR (Baes et al., 1994, *Mol. Cell. Biol.* 14(3):1544-1552) in the overlapping regions.

The present invention also relates to isolated nucleic acid fragments of nNR7 (SEQ ID NO: 1) which encode mRNA expressing a biologically active novel human nuclear receptor. Any such nucleic acid fragment will encode either a protein or protein fragment comprising at least an intracellular DNA-binding domain and/or ligand binding domain, domains conserved throughout the human nuclear receptor family domain which exist in nNR7 (SEQ ID NO: 2). Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for nNR7 function.

The isolated nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).

The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.

A preferred aspect of the present invention is disclosed in Figure 1A-C and SEQ ID NO: 1, a human cDNA encoding a novel nuclear trans-acting receptor protein, nNR7, disclosed as follows:

TACGCCAAGC TCGAAATTAA CCCTCACTAA AGGGAACAAA AGCTGGAGCT
CCACCGCGGT GGC GGCCGCT CTAGAACTAG TGGATCCCCC GGGCTGCAGG
AATTTCGAATT CTCATAACCT ATGACTAGGA CGGGAAGAGG AAGCACTGCC
TTTACTTCAG TGGGAATCTC GGCCTCAGCC TGCAAGCCAA GTGTTACAG

TGAGAAAAGC AAGAGAATAA GCTAATACTC CTGTCCTGAA CAAGGCAGCG
 GCTCCTTGGT AAAGCTACTC CTTGATCGAT CCTTTGCACC GGATTGTTCA
 AAGTGGACCC CAGGGGAGAA GTCGGAGCAA AGAACTTACC ACCAAGCAGT
 CCAAGAGGCC CAGAAGCAAA CCTGGAGGTG AGACCCAAAG AAAGCTGGAA
 5 CCATGCTGAC TTTGTACACT GTGAGGACAC AGAGTCTGTT CCTGGAAAGC
 CCAGTGTCAG CGCAGATGAG GAAGTCGGAG GTCCCCAAAT CTGCCGTGTA
 TGTGGGGACA AGGCCACTGG CTATCACTTC AATGTCATGA CATGTGAAGG
 ATGCAAGGGC TTTTTCAGGA GGGCCATGAA ACGCAACGCC CGGCTGAGGT
 GCCCCTTCCG GAAGGGCGCC TGCGAGATCA CCCGGAAGAC CCGGCGACAG
 10 TGCCAGGCCT GCCGCCTGCG CAAGTGCCTG GAGAGCGGCA TGAAGAAGGA
 GATGATCATG TCCGACGAGG CCGTGGAGGA GAGGCGGGCC TTGATCAAGC
 GGAAGAAAAG TGAACGGACA GGGACTCAGC CACTGGGAGT GCAGGGGCTG
 ACAGAGGAGC AGCGGATGAT GATCAGGGAG CTGATGGACG CTCAGATGAA
 AACCTTTGAC ACTACCTTCT CCCATTTCAA GAATTTCCGG CTGCCAGGGG
 15 TGCTTAGCAG TGGCTGCGAG TTGCCAGAGT CTCTGCAGGC CCCATCGAGG
 GAAGAAGCTG CCAAGTGGAG CCAGGTCCGG AAAGATCTGT GCTCTTTGAA
 GGTCTCTCTG CAGCTGCGGG GGGAGGATGG CAGTGTCTGG AACTACAAAC
 CCCCAGCCGA CAGTGGCGGG AAAGAGATCT TCTCCCTGCT GCCCCACATG
 GCTGACATGT CAACCTACAT GTTCAAAGGC ATCATCAGCT TTGCCAAAGT
 20 CATCTCCTAC TTCAGGGACT TGCCCATCGA GGACCAGATC TCCCTGCTGA
 AGGGGGCCGC TTTCGAGCTG TGTCAACTGA GATTCAACAC AGTGTTC AAC
 GCGGAGACTG GAACCTGGGA GTGTGGCCGG CTGTCCTACT GCTTGGAAGA
 CACTGCAGGT GGCTTCCAGC AACTTCTACT GGAGCCCATG CTGAAATTCC
 ACTACATGCT GAAGAAGCTG CAGCTGCATG AGGAGGAGTA TGTGCTGATG
 25 CAGGCCATCT CCCTCTTCTC CCCAGACCGC CCAGGTGTGC TGCAGCACCG
 CGTGGTGGAC CAGCTGCAGG AGCAATTCGC CATTACTCTG AAGTCCTACA
 TTGAATGCAA TCGGCCCCAG CCTGCTCATA GGTCTTTGTT CCTGAAGATC
 ATGGCTATGC TCACCGAGCT CCGCAGCATC AATGCTCAGC ACACCCAGCG
 GCTGCTGCGC ATCCAGGACA TACACCCCTT TGCTACGCCC CTCATGCAGG
 30 AGTTGTTTCGG CATCACAGGT AGCTGAGCGG CTGCCCTTGG GTGACACCTC
 CGAGAGGCAG CCAGACCCAG AGCCCTCTGA GCCGCCACTC CCGGGCCAAG
 ACAGATGGAC ACTGCCAAGA GCCGACAATG CCCTGCTGGC CTGTCTCCCT
 AGGGAATTCC TGCTATGACA GCTGGCTAGC ATTCTCAGG AAGGACATGG
 GTGCCCCCA CCCCCAGTTC AGTCTGTAGG GAGTGAAGCC ACAGATTCTT
 35 ACGTGGAGAG TGCATGACC TGTAGGTCAG GACCATCAGA GAGGCAAGGT
 TGCCCTTTCC TTTTAAAAGG CCCTGTGGTC TGGGGAGAAA TCCCTCAGAT

CCCACTAAAG TGTCAAGGTG TGGAAGGGAC CAAGCGACCA AGGATAGGCC
 ATCTGGGGTC TATGCCCACA TACCCACGTT TGTTCGCTTC CTGAGTCTTT
 TCATTGCTAC CTCCTAATAGT CCTGTCTCCC ACTTCCCCTC CGTTCCCCTC
 CTCTTCCGAG CTGCTTTGTG GGCTCCAGGC CTGTACTCAT CGGCAGGTGC
 5 ATGAGTATCT GTGGGAGTCC TCTAGAGAGA TGAGAAGCCA GGAGGCCTGC
 ACCAAATGTC AGAAGCTTGG CATGACCTCA TTCCGGCCAC ATCATTCTGT
 GTCTCTGCAT CCATTTGAAC ACATTATTAA GCACCGATAA TAGGTAGCCT
 GCTGTGGGGT ATACAGCATT GACTCAGATA TAGATCCTGA GCTCACAGAG
 TTTATAGTTA AAAAAACAAA CAGAAACACA AACAATTTGG ATCAAAGGA
 10 GAAATGATAA GTGACAAAAG CAGCACAAGG AATTTCCCTG TGTGGATGCT
 GAGCTGTGAT GGCGGGCACT GGGTACCCAA GTGAAGGTTT CCGAGGACAT
 GAGTCTGTAG GAGCAAGGGC ACAAACCTGCA GCTGTGAGTG CGTGTGTGTG
 ATTTGGTGTA GGTAGGTCTG TTTGCCACTT GATGGGGCCT GGGTTTGTTC
 CTGGGGCTGG AATGCTGGGT ATGCTCTGTG ACAAGGCTAC GCTGACAATC
 15 AGTTAAACAC ACCGGAGAAG AACCATTAC ATGCACCTTA TATTTCTGTG
 TACACATCTA TTCTCAAAGC TAAAGGGTAT GAAAGTGCCT GCCTTGTTTA
 TAGCCACTTG TGAGTAAAAA TTTTTTTGCA TTTTCACAAA TTATACTTTA
 TATAAGGCAT TCCACACCTA AGAACTAGTT TTGGGAAATG TAGCCCTGGG
 TTTAATGTCA AATCAAGGCA AAAGGAATTA AATAATGTAC TTTTGGCTAG
 20 AGGGGTAAAC TTTTTTGGCC TTTTCTGGG GAAAATAATG TGGGGGTGTG
 GGAATTGCGA TTCGATATCA AGCTTATCGA TACCGTCGAC CTCGAGGGGG
 GGCCCGGTAC CCAATTCGCC CTATAGTGAG TCGTATTACA ATT
 (SEQ ID NO: 1).

The above-exemplified isolated DNA molecule, shown in
 25 Figure 1A-C and set forth as SEQ ID NO:1, contains an open reading
 frame from nucleotide 276 to nucleotide 1673, with a "TGA" termination
 codon from nucleotides 1674-1676. This open reading frame encodes a
 human nNR7 receptor, a 466 amino acid protein shown in Figures 2A-C
 and Figure 3 and as set forth in SEQ ID NO:2.

30 Therefore, the present invention also relates to a
 substantially purified form of the novel nuclear trans-acting receptor
 protein, nNR7, shown in Figures 2A-C and Figure 3 and as set forth in
 SEQ ID NO: 2, disclosed as follows:

SILCTGLFKV DPRGEVGAKN LPPSSPRGPE ANLEVRPKES WNHADVFHCE
 35 DTESVPGKPS VNADEEVGGP QICRVCGDKA TGYHFNVMTC EGCKGFFRRA
 MKRNARLRCP FRKGACEITR KTRRQCQACR LRKCLES GMK KEMIMSDEAV

EERRALIKRK KSERTGTQPL GVQGLTEEQR MMIRELMDAQ MKTFDITTFSH
 FKNFRLPGVL SSGCELPESL QAPSREEAAK WSQVRKDLCS LKVSLLQLRGE
 DGSVWNYKPP ADSGGKEIFS LLPHMADMST YMFKGIISFA KVISYFRDLP
 IEDQISLLKG AAFELCQLRF NTVFNAETGT WECGRLSYCL EDTAGGFQQL
 5 LLEPMLKFHY MLKKLQLHEE EYVLMQAISL FSPDRPGVLQ HRVVDQLQEQ
 FAITLKSYIE CNRPQPAHRF LFLKIMAMLT ELRSINAQHT QRLRLRIQDIH
 PFATPLMQEL FGITGS (SEQ ID NO: 2).

The present invention also relates to biologically functional
 derivatives and/or mutants of nNR7 as set forth as SEQ ID NO: 2,
 10 including but not necessarily limited to amino acid substitutions,
 deletions, additions, amino terminal truncations and carboxy-terminal
 truncations such that these mutations provide for proteins or protein
 fragments of diagnostic, therapeutic or prophylactic use and would be
 useful for screening for agonists and/or antagonists of nNR7 function.

15 Another exemplification of the present invention relates to an
 isolated DNA molecule which comprises the nucleotide sequence as
 disclosed in Figure 4A-C and as set forth in SEQ ID NO:17. The initial
 exemplified cDNA molecule disclosed in Figure 1A-C and set forth as
 SEQ ID NO:1 does not contain a starting Met. Therefore, extension of
 20 the nNR7 5'-end sequence was continued. Three clones from 5'-end
 RACE (rapid amplification of cDNA end) showed divergence from the
 original cDNA as set forth in SEQ ID NO:1. One of these clones was
 shown to contain an initiating Met with an inframe stop codon in front.
 This DNA molecule is set forth herein in Figure 4A-C and is set forth as
 25 SEQ ID NO:17. This DNA molecule encodes a complete reading frame
 for an nNR7 type nuclear receptor and is referred herein as nNR7-1, and
 is set forth in Figures 5A-C and Figure 6, as well as SEQ ID NO:18.

This portion of the present invention also relates to sent
 invention relates to isolated nucleic acid fragments of SEQ ID NO: 17
 30 which encode mRNA expressing a biologically active novel human
 nuclear receptor. Any such nucleic acid fragment will encode either a
 protein or protein fragment comprising at least an intracellular DNA-
 binding domain and/or ligand binding domain, domains conserved
 throughout the human nuclear receptor family domain which exist in
 35 nNR7-1 (SEQ ID NO: 18). Any such polynucleotide includes but is not
 necessarily limited to nucleotide substitutions, deletions, additions,

amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists for nNR7-1

5 function.

The isolated nucleic acid molecule of this portion of the invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic
10 DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).

The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain
15 the substantially purified nucleic acid molecules disclosed throughout this specification.

An especially preferred aspect of the present invention is disclosed in Figure 4A-C and SEQ ID NO: 17, a human cDNA encoding a novel nuclear trans-acting receptor protein, nNR7-1, disclosed as
20 follows:

```
TCCATCCTAA TACGACTCAC TATAGGGCTC GAGCGGCCGC CCGGGCAGGT
CTTTTGGCCT GCTGGGTTAG TGCTGGCAGC CCCCTGAGGC CAAGGACAGC
AGCATGACAG TCACCAGGAC TCACCACTTC AAGGAGGGGT CCCTCAGAGC
ACCTGCCATA CCCCTGCACA GTGCTGCGGC TGAGTTGGCT TCAAACCATC
25 CAAGAGGCCC AGAAGCAAAC CTGGAGGTGA GACCCAAAGA AAGCTGGAAC
CATGCTGACT TTGTACACTG TGAGGACACA GAGTCTGTTC CTGGAAAGCC
CAGTGTCAAC GCAGATGAGG AAGTCGGAGG TCCCCAAATC TGCCGTGTAT
GTGGGGACAA GGCCACTGGC TATCACTTCA ATGTCATGAC ATGTGAAGGA
TGCAAGGGCT TTTTCAGGAG GGCCATGAAA CGCAACGCCC GGCTGAGGTG
30 CCCCTTCCGG AAGGGCGCCT GCGAGATCAC CCGGAAGACC CGGCGACAGT
GCCAGGCCTG CCGCCTGCGC AAGTGCCTGG AGAGCGGCAT GAAGAAGGAG
ATGATCATGT CCGACGAGGC CGTGGAGGAG AGGCGGGCCT TGATCAAGCG
GAAGAAAAGT GAACGGACAG GGAATCAGCC ACTGGGAGTG CAGGGGCTGA
CAGAGGAGCA GCGGATGATG ATCAGGGAGC TGATGGACGC TCAGATGAAA
35 ACCTTTGACA CTACCTTCTC CCATTTCAAG AATTTCCGGC TGCCAGGGGT
GCTTAGCAGT GGCTGCGAGT TGCCAGAGTC TCTGCAGGCC CCATCGAGGG
```

AAGAAGCTGC CAAGTGGAGC CAGGTCCGGA AAGATCTGTG CTCTTTGAAG
GTCTCTCTGC AGCTGCGGGG GGAGGATGGC AGTGTCTGGA ACTACAAACC
CCCAGCCGAC AGTGGCGGGA AAGAGATCTT CTCCCTGCTG CCCCACATGG
CTGACATGTC AACCTACATG TTCAAAGGCA TCATCAGCTT TGCCAAAGTC
5 ATCTCCTACT TCAGGGACTT GCCCATCGAG GACCAGATCT CCCTGCTGAA
GGGGGCCGCT TTCGAGCTGT GTCAACTGAG ATTCAACACA GTGTTCAACG
CGGAGACTGG AACCTGGGAG TGTGGCCGGC TGTCTACTG CTTGGAAGAC
ACTGCAGGTG GCTTCCAGCA ACTTCTACTG GAGCCCATGC TGAAATTCCA
CTACATGCTG AAGAAGCTGC AGCTGCATGA GGAGGAGTAT GTGCTGATGC
10 AGGCCATCTC CCTCTTCTCC CCAGACCGCC CAGGTGTGCT GCAGCACCGC
GTGGTGGACC AGCTGCAGGA GCAATTGCGC ATTACTCTGA AGTCCTACAT
TGAATGCAAT CGGCCCCAGC CTGCTCATAG GTTCTTGTTT CTGAAGATCA
TGGCTATGCT CACCGAGCTC CGCAGCATCA ATGCTCAGCA CACCCAGCGG
CTGCTGCGCA TCCAGGACAT ACACCCCTTT GCTACGCCCC TCATGCAGGA
15 GTTGTTCGGC ATCACAGGTA GCTGAGCGGC TGCCCTTGGG TGACACCTCC
GAGAGGCAGC CAGACCCAGA GCCCTCTGAG CCGCCACTCC CGGGCCAAGA
CAGATGGACA CTGCCAAGAG CCGACAATGC CCTGCTGGCC TGTCTCCCTA
GGGAATTCCT GCTATGACAG CTGGCTAGCA TTCTCAGGA AGGACATGGG
TGCCCCCCAC CCCCAGTTCA GTCTGTAGGG AGTGAAGCCA CAGATTCTTA
20 CGTGGAGAGT GCACTGACCT GTAGGTCAGG ACCATCAGAG AGGCAAGGTT
GCCCTTTCCT TTTAAAAGGC CCTGTGGTCT GGGGAGAAAT CCCTCAGATC
CCACTAAAGT GTCAAGGTGT GGAAGGGACC AAGCGACCAA GGATAGGCCA
TCTGGGGTCT ATGCCACAT ACCCACGTTT GTTCGCTTCC TGAGTCTTTT
CATTGCTACC TCTAATAGTC CTGTCTCCCA CTTCCCACTC GTTCCCCTCC
25 TCTTCCGAGC TGCTTTGTGG GCTCCAGGCC TGTACTCATC GGCAGGTGCA
TGAGTATCTG TGGGAGTCCT CTAGAGAGAT GAGAAGCCAG GAGGCCTGCA
CCAAATGTCA GAAGCTTGGC ATGACCTCAT TCCGGCCACA TCATTCTGTG
TCTCTGCATC CATTTGAACA CATTATTAAG CACCGATAAT AGGTAGCCTG
CTGTGGGGTA TACAGCATTG ACTCAGATAT AGATCCTGAG CTCACAGAGT
30 TTATAGTTAA AAAACAAAC AGAAACACAA ACAATTTGGA TCAAAAGGAG
AAATGATAAG TGACAAAAGC AGCACAAGGA ATTTCCCTGT GTGGATGCTG
AGCTGTGATG GCGGGCACTG GGTACCCAAG TGAAGGTTC CGAGGACATG
AGTCTGTAGG AGCAAGGGCA CAACTGCAG CTGTGAGTGC GTGTGTGTGA
TTTGGTGTAG GTAGGTCTGT TTGCCACTTG ATGGGGCCTG GGTTTGTTCC
35 TGGGGCTGGA ATGCTGGGTA TGCTCTGTGA CAAGGCTACG CTGACAATCA
GTTAAACACA CCGGAGAAGA ACCATTTACA TGCACCTTAT ATTTCTGTGT

ACACATCTAT TCTCAAAGCT AAAGGGTATG AAAGTGCCTG CCTTGTTTAT
 AGCCACTTGT GAGTAAAAAT TTTTTTGCAT TTTCACAAAT TATACTTTAT
 ATAAGGCATT CCACACCTAA GAACTAGTTT TGGGAAATGT AGCCCTGGGT
 TTAATGTCAA ATCAAGGCAA AAGGAATTAA ATAATGTACT TTTGGCTAGA
 5 GGGGTAAACT TTTTGGCCT TTTTCTGGGG AAAATAATGT GGGGGTGTGG
 (SEQ ID NO: 17).

The above-exemplified isolated DNA molecule, shown in
 Figure 4A-C and set forth as SEQ ID NO:17, contains an open reading
 frame from nucleotide 104 to nucleotide 1522, with a "TGA" termination
 10 codon from nucleotides 1523-1525. This open reading frame encodes a
 human nNR7-1 receptor, a 473 amino acid protein shown in
 Figures 5A-C and Figure 6 and as set forth in SEQ ID NO:18.

Therefore, the present invention also relates to a
 substantially purified form of the novel nuclear trans-acting receptor
 15 protein, nNR7-1, which is shown in Figures 5A-C and Figure 6 and as
 set forth in SEQ ID NO: 18, disclosed as follows:

MTVTRTHHFK EGSLRAPAIP LHSAAELAS NHPRGPEANL EVRPKESWNH
 ADFVHCEDTE SVPGKPSVNA DEEVGGPQIC RVC GDKATGY HFNVMTCCEGC
 KGFFRRAMKR NARLRCPFRK GACEITRKTR RQCQACRLRK CLESGMKKEM
 20 IMSDEAVEER RALIKRKKSE RTGTQPLGVQ GLTEEQRMMI RELMDAQMKT
 FDTTFSHFKN FRLPGVLSSG CELPESLQAP SREEAAKWSQ VRKDLCSLKV
 SLQLRGEDGS VWNYPKPPADS GGKEIFSLLP HMADMSTYMF KGIISFAKVI
 SYFRDLPIED QISLLKGA AF ELCQLRFNTV FNAETGTWEC GRLSYCLEDT
 AGGFQQLLLE PMLKFHYMLK KLQLHEEEYV LMQAISLFSP DRPGVLQHRV
 25 VDQLQE QFAI TLKSYIECNR PQPAHRFLFL KIMAMLTCLR SINAQHTQRL
 LRIQDIHPFA TPLMQELFGI TGS (SEQ ID NO:18).

A comparison of the nucleotide sequences and related open
 reading frames of SEQ ID NO:1 and SEQ ID NO:17 which encode nNR7
 (SEQ ID NO:2) and nNR7-1 (SEQ ID NO:18) reveals nucleotide sequence
 30 divergence at the 5' end of these cDNA clones which results in different
 amino terminal regions for nNR7-1 compared to nNR7. More
 specifically, an open reading frame from nucleotide 276 to nucleotide 350
 of SEQ ID NO:1 encodes the NH₂ terminal 25 amino acids of nNR7, as
 set forth in Figure 3 and SEQ ID NO:2. There is no initiating
 35 methionine residue in nNR7. In contrast, an initiating codon for
 methionine is present in SEQ ID NO:17 (nucleotide residue 104-106) and

the 5' portion of the coding region of this cDNA clone differs from nucleotide 104 through nucleotide 198 of SEQ ID NO:17, which encodes the NH₂ terminal 32 amino acids of nNR7-1 (SEQ ID NO:18) that differ from the initial 25 amino acid residues of nNR7. In other words, nNR7
5 and nNR7-1 are identical from amino acid 26-466 of nNR7 and amino acid 33-473 of nNR7-1.

The present invention also relates to biologically functional derivatives and/or mutants of nNR7 as set forth as SEQ ID NO: 18, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal
10 truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and would be useful for screening for agonists and/or antagonists of nNR7-1 function. As with many proteins, it is possible to modify many of the amino acids of nNR7 or nNR7-1, particularly those which are not found in the DNA
15 binding domain, and still retain substantially the same biological activity as the original receptor. Thus this invention includes modified nNR7 and nNR7-1 polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same
20 biological activity as nNR7 and nNR7-1. It is generally accepted that single amino acid substitutions do not usually alter the biological activity of a protein (see, e.g., Molecular Biology of the Gene, Watson et al., 1987, Fourth Ed., The Benjamin/Cummings Publishing Co., Inc., page 226; and Cunningham & Wells, 1989, *Science* 244:1081-1085). Accordingly,
25 the present invention includes polypeptides where one amino acid substitution has been made in SEQ.ID.NO.:2 or SEQ ID NO:18 wherein the polypeptides still retain substantially the same biological activity as nNR7 or nNR7-1. The present invention also includes polypeptides where two or more amino acid substitutions have been made in
30 SEQ.ID.NO.:2 or SEQ ID NO:18 wherein the polypeptides still retain substantially the same biological activity as the wild type protein. In particular, the present invention includes embodiments where the above-described substitutions are conservative substitutions. In particular, the present invention includes embodiments where the
35 above-described substitutions do not occur in the DNA-binding domain of nNR7 or nNR7-1. When deciding which amino acid residues of nNR7 or

nNR7-1 may be substituted to produce polypeptides that are functional equivalents of nNR7 or nNR7-1, one skilled in the art would be guided by a comparison of the amino acid sequence of nNR7 or nNR7-1 with the amino acid sequences of related proteins. One skilled in the art would
5 also recognize that polypeptides that are functional equivalents of nNR7 or nNR7-1 and have changes from the amino acid sequence of these respective proteins that are small deletions or insertions of amino acids could also be produced by following the same guidelines, (i.e., minimizing the differences in amino acid sequence between nNR7 or
10 nNR7-1 and related proteins. Small deletions or insertions are generally in the range of about 1 to 5 amino acids. The effect of such small deletions or insertions on the biological activity of the modified nNR7 or nNR7-1 polypeptide can easily be assayed by producing the polypeptide synthetically or by making the required changes in DNA encoding nNR7
15 or nNR7-1 and then expressing the DNA recombinantly and assaying the protein produced by such recombinant expression.

The present invention also relates to isolated nucleic acid molecules which are fusion constructions expressing fusion proteins useful in assays to identify compounds which modulate wild-type
20 human nNR7 and/or nNR7-1 activity. A preferred aspect of this portion of the invention includes, but is not limited to, glutathione S-transferase GST-nNR7 and/or GST-nNR7-1 fusion constructs. These fusion constructs include, but are not limited to, all or a portion of the ligand-binding domain of nNR7 and/or nNR7-1, respectively, as an in-frame
25 fusion at the carboxy terminus of the GST gene. The disclosure of SEQ ID Nos:1, 2, 17 and 18 allow the artisan of ordinary skill to construct any such nucleic acid molecule encoding a GST-nuclear receptor fusion protein. Soluble recombinant GST-nuclear receptor fusion proteins may be expressed in various expression systems, including *Spodoptera*
30 *frugiperda* (Sf21) insect cells (Invitrogen) using a baculovirus expression vector (e.g., Bac-N-Blue DNA from Invitrogen or pAcG2T from Pharmingen).

It is also within the purview of the artisan of ordinary skill to use the DNA molecules of the present invention to construct DNA
35 expression vectors for use in transactivation assays to identify modulators of nNR7, nNR7-1 and/or DNA molecules or proteins which

interact with nNR7-like proteins. For example, a portion of SEQ ID NO:1 or SEQ ID NO:17 may be fused downstream of an active promoter, such as a CMV promoter fragment, so as to overexpress a receptor protein. A second construct includes regulatory regions from the human CYP3A4 gene (such as the human CYP3A4 promoter region or a response element [e.g., SEQ ID NO:24]) fused to a reporter gene, such as SEAP (secreted placental alkaline phosphatase, LacZ or chloremphenicol acetyl transferase [CAT]). These constructs may then be utilized in a transactivation assay to identify modulators of CYP3A4 levels *in vivo*. It will be known that various modifications to either or both the receptor construct and/or the reporter construct may be made without effecting the effectiveness of the transactivation assay. For example, the native nNR7 or nNR7-1 promoter may be utilized instead of a hybrid promoter such as the CMV promoter. Or it may be useful to use a different reporter gene, such as LacZ.

Therefore, the present invention is also directed to methods for screening for compounds which modulate the expression of DNA or RNA encoding a human nNR7 and/or nNR7-1 protein. Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non-proteinaceous organic molecules. Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding human nNR7 and/or nNR7-1, or the function of human nNR7 and/or nNR7-1. Compounds that modulate the expression of DNA or RNA encoding human nNR7 and/or nNR7-1 or the biological function thereof may be detected by a variety of assays. The assay may be a simple "yes/no" assay to determine whether there is a change in expression or function. The assay may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample. Kits containing human nNR7 and/or nNR7-1, antibodies to human nNR7 and/or nNR7-1, or modified human nNR7 and/or nNR7-1 may be prepared by known methods for such uses.

The DNA molecules, RNA molecules, recombinant protein and antibodies of the present invention may be used to screen and measure levels of human nNR7 and/or nNR7-1. The recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing

of human nNR7 and/or nNR7-1. Such a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier would further comprise reagents such as recombinant nNR7 and/or nNR7-1 or anti-nNR7 and/or nNR7-1
5 antibodies suitable for detecting human nNR7 and/or nNR7-1. The carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.

Pharmaceutically useful compositions comprising modulators of human nNR7 and/or nNR7-1 may be formulated
10 according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective
15 amount of the protein, DNA, RNA, modified human nNR7 and/or nNR7-1, or either nNR7 and/or nNR7-1 agonists or antagonists.

Therefore, the present invention includes assays by which modulators of cytochrome P450 enzymes, especially CYP 450 enzymes which comprise the response element 5'-TGAAGCTCAAAGGAGGTCA-
20 3' (SEQ ID NO:24), and especially human CYP3A4. Methods for identifying agonists and antagonists of other receptors are well known in the art and can be adapted to identify compounds which effect *in vivo* levels of CYP3A4. Accordingly, the present invention includes a method for determining whether a substance is a potential modulator of
25 CYP3A4 levels that comprises:

- (a) transfecting or transforming cells with an expression vector encoding nNR7 or nNR7-1, also known as the receptor vector;
- (b) transfecting or transforming the cells of step (a) with
30 second expression vector which comprises a response element known to bind nNR7 or nNR7-1 and a promoter fragment fused upstream of a reporter gene, also known as a reporter vector.
- (c) allowing the transfected cells to grow for a time sufficient to allow nNR7 or nNR7-1 to be expressed;
- 35 (d) exposing the test cells to a substance while not exposing control cells to the test substance;

- (e) measuring the expression of the reporter gene in both the test cells and control cells; where if the amount of binding of expression in the test cells is greater than in the control cells, the substance may enhance or act as an agonist to CYP3A4 activity, whereas the opposite effect may suggest a possible antagonist of CYP3A4 activity.

The conditions under which step (d) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

Alternatively, the transactivation assay may be carried out as follows: (a) provide test cells by transfecting cells with a receptor expression vector that directs the expression of nNR7 or nNR7-1 in the cells;

(b) providing test cells by transfecting the cells of step (a) with a second reporter expression vector that directs expression of a reporter gene under control of a regulatory element which is responsive to nNR7 or nNR7-1

(b) exposing the test cells to the substance;

(c) measuring the amount of binding of expression of the reporter gene;

(d) comparing the amount of expression of the reporter gene in the test cells with the amount of expression of the reporter gene in control cells that has been transfected with a reporter vector of step (b) but not a receptor vector of step (a).

Therefore, it is evident that any number of variations known to one of skill in the art may be utilized in order to provide for an assay to measure the effect of a substance on the ability of the nuclear receptor proteins of the present invention to effect transcription of a promoter of interest (*e.g.*, effecting CYP3A4 gene expression).

The present invention also includes a method for determining whether a substance is capable of binding to nNR7 and/or nNR7-1, *i.e.*, whether the substance is a potential agonist or an antagonist of nNR7 and/or nNR7-1, where the method comprises:

(a) providing test cells by transfecting cells with an expression vector that directs the expression of nNR7 and/or nNR7-1 in the cells;

(b) exposing the test cells to the substance;

5 (c) measuring the amount of binding of the substance to nNR7 and/or nNR7-1;

(d) comparing the amount of binding of the substance to nNR7 or nNR7-1 in the test cells with the amount of binding of the substance to control cells that have not been transfected with nNR7 or nNR7-1; wherein if the amount of binding of the substance is greater in the test cells as compared to the control cells, the substance is capable of binding to nNR7 or nNR7-1. Determining whether the substance is actually an agonist or antagonist can then be accomplished by the use of functional assays such as the transactivation assay as described above.

15 The conditions under which step (b) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

20 The assays described above can be carried out with cells that have been transiently or stably transfected with nNR7 or nNR7-1. Transfection is meant to include any method known in the art for introducing nNR7 or nNR7-1 into the test cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection, lipofection, infection with a retroviral construct containing

25 nNR7 or nNR7-1, and electroporation.

Where binding of the substance or agonist to nNR7 or nNR7-1 is measured, such binding can be measured by employing a labeled substance or agonist. The substance or agonist can be labeled in any convenient manner known to the art, *e.g.*, radioactively, fluorescently, enzymatically.

30

In particular embodiments of the above-described methods, nNR7 or nNR7-1 has an amino acid sequence of SEQ ID NO:2.

The isolated nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or

35

noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).

- 5 It is known that there is a substantial amount of redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA sequences encode RNA comprising alternative codons which code for the eventual translation of the identical amino acid, as shown below:
- 10 A=Ala=Alanine: codons GCA, GCC, GCG, GCU
 C=Cys=Cysteine: codons UGC, UGU
 D=Asp=Aspartic acid: codons GAC, GAU
 E=Glu=Glutamic acid: codons GAA, GAG
 F=Phe=Phenylalanine: codons UUC, UUU
15 G=Gly=Glycine: codons GGA, GGC, GGG, GGU
 H=His =Histidine: codons CAC, CAU
 I=Ile =Isoleucine: codons AUA, AUC, AUU
 K=Lys=Lysine: codons AAA, AAG
 L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU
20 M=Met=Methionine: codon AUG
 N=Asp=Asparagine: codons AAC, AAU
 P=Pro=Proline: codons CCA, CCC, CCG, CCU
 Q=Gln=Glutamine: codons CAA, CAG
 R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU
25 S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU
 T=Thr=Threonine: codons ACA, ACC, ACG, ACU
 V=Val=Valine: codons GUA, GUC, GUG, GUU
 W=Trp=Tryptophan: codon UGG
 Y=Tyr=Tyrosine: codons UAC, UAU
30 Therefore, the present invention discloses codon redundancy which may result in differing DNA molecules expressing an identical protein. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in
35 the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed

protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide.

It is known that DNA sequences coding for a peptide
5 may be altered so as to code for a peptide having properties that are different than those of the naturally occurring peptide. Methods of altering the DNA sequences include but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or a
10 receptor for a ligand.

As used herein, "purified" and "isolated" are utilized interchangeably to stand for the proposition that the nucleic acid, protein, or respective fragment thereof in question has been substantially removed from its *in vivo* environment so that it may be
15 manipulated by the skilled artisan, such as but not limited to nucleotide sequencing, restriction digestion, site-directed mutagenesis, and subcloning into expression vectors for a nucleic acid fragment as well as obtaining the protein or protein fragment in pure quantities so as to afford the opportunity to generate polyclonal antibodies, monoclonal
20 antibodies, amino acid sequencing, and peptide digestion. Therefore, the nucleic acids claimed herein may be present in whole cells or in cell lysates or in a partially purified or substantially purified form. A nucleic acid is considered substantially purified when it is purified away from environmental contaminants. Thus, a nucleic acid sequence
25 isolated from cells is considered to be substantially purified when purified from cellular components by standard methods while a chemically synthesized nucleic acid sequence is considered to be substantially purified when purified from its chemical precursors.

The present invention also relates to recombinant vectors
30 and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.

Therefore, the present invention also relates to methods of expressing nNR7 and/or nNR7-1 and biological equivalents disclosed
35 herein, assays employing these recombinantly expressed gene products,

cells expressing these gene products, and agonistic and/or antagonistic compounds identified through the use of assays utilizing these recombinant forms, including, but not limited to, one or more modulators of the human nNR7 and/or nNR7-1 either through direct
5 contact LBD or through direct or indirect contact with a ligand which either interacts with the DBD or with the wild-type transcription complex which nNR7 and/or nNR7-1 interacts *in trans*, thereby modulating cell differentiation or cell development.

As used herein, a "biologically functional derivative" of a
10 wild-type human nNR7 and/or nNR7-1 possesses a biological activity that is related to the biological activity of the wild type human nNR7 and/or nNR7-1. The term "functional derivative" is intended to include the "fragments," "mutants," "variants," "degenerate variants,"
"analogs" and "homologues" of the wild type human nNR7 and/or nNR-1
15 protein. The term "fragment" is meant to refer to any polypeptide subset of wild-type human nNR7 and/or nNR7-1, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations. The term "mutant" is
20 meant to refer a subset of a biologically active fragment that may be substantially similar to the wild-type form but possesses distinguishing biological characteristics. Such altered characteristics include but are in no way limited to altered substrate binding, altered substrate affinity and altered sensitivity to chemical compounds affecting biological
25 activity of the human nNR7 and/or nNR7-1 or human nNR7 and/or nNR7-1 functional derivative. The term "variant" is meant to refer to a molecule substantially similar in structure and function to either the entire wild-type protein or to a fragment thereof. A molecule is
"substantially similar" to a wild-type human nNR7 and/or nNR7-1-like
30 protein if both molecules have substantially similar structures or if both molecules possess similar biological activity. Therefore, if the two molecules possess substantially similar activity, they are considered to be variants even if the structure of one of the molecules is not found in the other or even if the two amino acid sequences are not identical. The
term "analog" refers to a molecule substantially similar in function to
35 either the full-length human nNR7 and/or nNR7-1 protein or to a biologically functional derivative thereof.

Any of a variety of procedures may be used to clone human nNR7 and/or nNR7-1. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman, et al., 1988, *Proc. Natl. Acad. Sci. USA* 85: 8998-9002). 5' and/or 3' RACE may be performed to generate a full-length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of human nNR7 and/or nNR7-1 cDNA. These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the human nNR7 and/or nNR7-1 cDNA following the construction of a human nNR7 and/or nNR7-1-containing cDNA library in an appropriate expression vector system; (3) screening a human nNR7 and/or nNR7-1-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the human nNR7 and/or nNR7-1 protein; (4) screening a human nNR7 and/or nNR7-1-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the human nNR7 and/or nNR7-1 protein. This partial cDNA is obtained by the specific PCR amplification of human nNR7 and/or nNR7-1 DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other kinases which are related to the human nNR7 and/or nNR7-1 protein; (5) screening a human nNR7 and/or nNR7-1-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the human nNR7 and/or nNR7-1 protein. This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of human nNR7 and/or nNR7-1 cDNA identified as an EST as described above; or (6) designing 5' and 3' gene specific oligonucleotides using SEQ ID NO: 1 as a template so that either the full-length cDNA may be generated by known PCR techniques, or a portion of the coding region may be generated by these same known PCR techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a

full-length version of the nucleotide sequence encoding human nNR7 and/or nNR7-1.

It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cell types or species types, may be useful for isolating a nNR7 and/or nNR7-1-encoding DNA or a nNR7 and/or nNR7-1 homologue. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines other than human cells or tissue such as murine cells, rodent cells or any other such vertebrate host which may contain nNR7 and/or nNR7-1-encoding DNA. Additionally a nNR7 and/or nNR7-1 gene and homologues may be isolated by oligonucleotide- or polynucleotide-based hybridization screening of a vertebrate genomic library, including but not limited to, a murine genomic library, a rodent genomic library, as well as concomitant human genomic DNA libraries.

It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have nNR7 and/or nNR7-1 activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate a cDNA encoding nNR7 and/or nNR7-1 may be done by first measuring cell-associated nNR7 and/or nNR7-1 activity using any known assay available for such a purpose.

Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagene.

It is also readily apparent to those skilled in the art that DNA encoding human nNR7 and/or nNR7-1 may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techniques can be found in Sambrook, et al., *supra*.

In order to clone the human nNR7 and/or nNR7-1 gene by one of the preferred methods, the amino acid sequence or DNA sequence

of human nNR7 and/or nNR7-1 or a homologous protein may be necessary. To accomplish this, the nNR7 and/or nNR7-1 protein or a homologous protein may be purified and partial amino acid sequence determined by automated sequenators. It is not necessary to determine
5 the entire amino acid sequence, but the linear sequence of two regions of 6 to 8 amino acids can be determined for the PCR amplification of a partial human nNR7 and/or nNR7-1 DNA fragment. Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized. Because the genetic code is
10 degenerate, more than one codon may be used to encode a particular amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the human nNR7 and/or nNR7-1 sequence but others in the set will be capable of hybridizing to human nNR7 and/or nNR7-1
15 DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still sufficiently hybridize to the human nNR7 and/or nNR7-1 DNA to permit identification and isolation of human nNR7 and/or nNR7-1 encoding DNA. Alternatively, the nucleotide sequence of a region of an expressed sequence may be
20 identified by searching one or more available genomic databases. Gene-specific primers may be used to perform PCR amplification of a cDNA of interest from either a cDNA library or a population of cDNAs. As noted above, the appropriate nucleotide sequence for use in a PCR-based method may be obtained from SEQ ID NO: 1, either for the purpose of
25 isolating overlapping 5' and 3' RACE products for generation of a full-length sequence coding for human nNR7 and/or nNR7-1, or to isolate a portion of the nucleotide sequence coding for human nNR7 and/or nNR7-1 for use as a probe to screen one or more cDNA- or genomic-based libraries to isolate a full-length sequence encoding human nNR7
30 and/or nNR7-1-like proteins.

In one exemplified method, the human nNR7 full-length cDNA of the present invention were generated by screening a mixed cDNA library with DNA fragments corresponding to human AR, ERb, GR and VDR DNA binding domain regions. Positive clones were
35 excised from lZAPII phages and the plasmid DNA was sequenced directly M13 forward and reverse primers. A Blast search of the

sequence information was obtained using computer program PhredPhrap. A single cDNA clone was shown to comprise the open reading frame of a novel human nuclear receptor. DNA sequencing was continued from both 5' and 3' ends on nNR7, which identified the presence of an intron. A cDNA fragment flanking the intron region was retrieved via PCR using a first oligonucleotide primer pair and double nested primers. A prominent DNA fragment of ~1.5 kb was amplified from testis and brain cDNAs. The fragment was purified and subcloned into pCRII vector (Invitrogen, San Diego, CA). Automated sequencing was performed on several of the clones. The complete sequencing revealed a 3.1 kb cDNA which codes an authentic novel nuclear receptor, nNR7.

In a second exemplified method oligo primers were used to amplify nNR7 5' cDNA ends from human liver cDNA. DNA product from one round PCR reaction was gel purified, subcloned into a plasmid vector and subjected to nucleotide sequencing. Ambiguities and/or discrepancies between automated base calling in sequencing reads were visually examined and edited to the correct base call. One clone was found to have an open reading frame differing from the open reading frame disclosed for SEQ ID NO:1, such that this additional exemplified cDNA (as disclosed in SEQ ID NO:17) contains an in frame Met and upstream stop codons. The site of divergence (as discussed herein) is the same as the other two additional clones derived from 5'-RACE (rapid amplification of cDNA ends). The cDNA clone disclosed in Figure 4A-4C and set forth as SEQ ID NO:17 is a complementary DNA sequence to a completely processed mRNA which expresses an especially preferred nuclear receptor protein of the present invention (i.e, nNR7-1).

A variety of mammalian expression vectors may be used to express recombinant human nNR7 and/or nNR7-1 in mammalian cells. Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned DNA and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, blue green algae, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector

should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one which causes mRNAs to be initiated at high frequency. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses.

Commercially available mammalian expression vectors which may be suitable for recombinant human nNR7 and/or nNR7-1 expression, include but are not limited to pcDNA3.1 (Invitrogen), pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Biolabs), pcDNA1, pcDNA1amp (Invitrogen), pcDNA3 (Invitrogen), pMC1neo (Stratagene), pXT1 (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and lZD35 (ATCC 37565).

A variety of bacterial expression vectors may be used to express recombinant human nNR7 and/or nNR7-1 in bacterial cells. Commercially available bacterial expression vectors which may be suitable for recombinant human nNR7 and/or nNR7-1 expression include, but are not limited to pCRII (Invitrogen), pCR2.1 (Invitrogen), pQE (Qiagen), pET11a (Novagen), lambda gt11 (Invitrogen), and pKK223-3 (Pharmacia).

A variety of fungal cell expression vectors may be used to express recombinant human nNR7 and/or nNR7-1 in fungal cells. Commercially available fungal cell expression vectors which may be suitable for recombinant human nNR7 and/or nNR7-1 expression include but are not limited to pYES2 (Invitrogen) and *Pichia* expression vector (Invitrogen).

A variety of insect cell expression vectors may be used to express recombinant receptor in insect cells. Commercially available insect cell expression vectors which may be suitable for recombinant expression of human nNR7 and/or nNR7-1 include but are not limited to

pBlueBacIII and pBlueBacHis2 (Invitrogen), and pAcG2T (Pharmingen).

5 An expression vector containing DNA encoding a human nNR7 and/or nNR7-1-like protein may be used for expression of human nNR7 and/or nNR7-1 in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila*-
10 and silkworm-derived cell lines. Cell lines derived from mammalian species which may be suitable and which are commercially available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), Saos-2 (ATCC HTB-85), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7
15 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171) and CPAE (ATCC CCL 209).

The expression vector may be introduced into host cells via
20 any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation. The expression vector-containing cells are individually analyzed to determine whether they produce human nNR7 and/or nNR7-1 protein. Identification of human nNR7 and/or nNR7-1 expressing cells may be
25 done by several means, including but not limited to immunological reactivity with anti-human nNR7 and/or nNR7-1 antibodies, labeled ligand binding and the presence of host cell-associated human nNR7 and/or nNR7-1 activity.

The cloned human nNR7 and/or nNR7-1 cDNA obtained
30 through the methods described above may be recombinantly expressed by molecular cloning into an expression vector (such as pcDNA3.1, pQE, pBlueBacHis2 and pLITMUS28) containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant human
35 nNR7 and/or nNR7-1. Techniques for such manipulations can be found described in Sambrook, et al., *supra*, are discussed at length in the

Example section and are well known and easily available to the artisan of ordinary skill in the art.

Expression of human nNR7 and/or nNR7-1 DNA may also be performed using *in vitro* produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.

To determine the human nNR7 and/or nNR7-1 cDNA sequence(s) that yields optimal levels of human nNR7 and/or nNR7-1, cDNA molecules including but not limited to the following can be constructed: a cDNA fragment containing the full-length open reading frame for human nNR7 and/or nNR7-1 as well as various constructs containing portions of the cDNA encoding only specific domains of the protein or rearranged domains of the protein. All constructs can be designed to contain none, all or portions of the 5' and/or 3' untranslated region of a human nNR7 and/or nNR7-1 cDNA. The expression levels and activity of human nNR7 and/or nNR7-1 can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells. Following determination of the human nNR7 and/or nNR7-1 cDNA cassette yielding optimal expression in transient assays, this nNR7 and/or nNR7-1 cDNA construct is transferred to a variety of expression vectors (including recombinant viruses), including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, bacteria, and yeast cells.

The present invention also relates to polyclonal and monoclonal antibodies raised in response to either the human form of nNR7 and/or nNR7-1 disclosed herein, or a biologically functional derivative thereof. It will be especially preferable to raise antibodies against epitopes within the NH₂-terminal domain of nNR7 and/or nNR7-1, which show the least homology to other known proteins belonging to the human nuclear receptor superfamily.

Recombinant nNR7 and/or nNR7-1 protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full-length nNR7

and/or nNR7-1 protein, or polypeptide fragments of nNR7 and/or nNR7-1 protein. Additionally, polyclonal or monoclonal antibodies may be raised against a synthetic peptide (usually from about 9 to about 25 amino acids in length) from a portion of the protein as disclosed in SEQ ID NO: 2 or SEQ ID NO:18. Monospecific antibodies to human nNR7 and/or nNR7-1 are purified from mammalian antisera containing antibodies reactive against human nNR7 and/or nNR7-1 or are prepared as monoclonal antibodies reactive with human nNR7 and/or nNR7-1 using the technique of Kohler and Milstein (1975, *Nature* 256: 495-497).

Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for human nNR7 and/or nNR7-1. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with human nNR7 and/or nNR7-1, as described above. Human nNR7 and/or nNR7-1-specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with an appropriate concentration of human nNR7 and/or nNR7-1 protein or a synthetic peptide generated from a portion of human nNR7 and/or nNR7-1 with or without an immune adjuvant.

Preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 mg and about 1000 mg of human nNR7 and/or nNR7-1 protein associated with an acceptable immune adjuvant. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing *Corynebacterium parvum* and tRNA. The initial immunization consists of human nNR7 and/or nNR7-1 protein or peptide fragment thereof in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are generally given an equal amount of human nNR7 and/or nNR7-1 in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after

each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20°C.

Monoclonal antibodies (mAb) reactive with human nNR7 and/or nNR7-1 are prepared by immunizing inbred mice, preferably Balb/c, with human nNR7 and/or nNR7-1 protein. The mice are immunized by the IP or SC route with about 1 mg to about 100 mg, preferably about 10 mg, of human nNR7 and/or nNR7-1 protein in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 1 to about 100 mg of human nNR7 and/or nNR7-1 in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes, from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS1/Ag 4-1, MPC-11, S-194 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using human nNR7 and/or nNR7-1 as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, 1973, *Soft Agar Techniques*, in *Tissue Culture Methods and Applications*, Kruse and Paterson, Eds., Academic Press.

Monoclonal antibodies are produced *in vivo* by injection of
pristine primed Balb/c mice, approximately 0.5 ml per mouse, with
about 2×10^6 to about 6×10^6 hybridoma cells about 4 days after priming.
Ascites fluid is collected at approximately 8-12 days after cell transfer
5 and the monoclonal antibodies are purified by techniques known in the
art.

In vitro production of anti-human nNR7 and/or nNR7-1
mAb is carried out by growing the hybridoma in DMEM containing
about 2% fetal calf serum to obtain sufficient quantities of the specific
10 mAb. The mAb are purified by techniques known in the art.

Antibody titers of ascites or hybridoma culture fluids are
determined by various serological or immunological assays which
include, but are not limited to, precipitation, passive agglutination,
enzyme-linked immunosorbent antibody (ELISA) technique and
15 radioimmunoassay (RIA) techniques. Similar assays are used to detect
the presence of human nNR7 and/or nNR7-1 in body fluids or tissue and
cell extracts.

It is readily apparent to those skilled in the art that the
above described methods for producing monospecific antibodies may be
20 utilized to produce antibodies specific for human nNR7 and/or nNR7-1
peptide fragments, or full-length human nNR7 and/or nNR7-1.

Human nNR7 and/or nNR7-1 antibody affinity columns are
made, for example, by adding the antibodies to Affigel-10 (Biorad), a gel
support which is pre-activated with N-hydroxysuccinimide esters such
25 that the antibodies form covalent linkages with the agarose gel bead
support. The antibodies are then coupled to the gel via amide bonds with
the spacer arm. The remaining activated esters are then quenched with
1M ethanolamine HCl (pH 8.0). The column is washed with water
followed by 0.23 M glycine HCl (pH 2.6) to remove any non-conjugated
30 antibody or extraneous protein. The column is then equilibrated in
phosphate buffered saline (pH 7.3) and the cell culture supernatants or
cell extracts containing full-length human nNR7 and/or nNR7-1 or
human nNR7 and/or nNR7-1 protein fragments are slowly passed
through the column. The column is then washed with phosphate
35 buffered saline until the optical density (A280) falls to background, then
the protein is eluted with 0.23 M glycine-HCl (pH 2.6). The purified

human nNR7 and/or nNR7-1 protein is then dialyzed against phosphate buffered saline.

Levels of human nNR7 and/or nNR7-1 in host cells is quantified by a variety of techniques including, but not limited to, immunoaffinity and/or ligand affinity techniques. nNR7 and/or nNR7-1-specific affinity beads or nNR7 and/or nNR7-1-specific antibodies are used to isolate ³⁵S-methionine labeled or unlabelled nNR7 and/or nNR7-1. Labeled nNR7 and/or nNR7-1 protein is analyzed by SDS-PAGE. Unlabelled nNR7 and/or nNR7-1 protein is detected by Western blotting, ELISA or RIA assays employing either nNR7 and/or nNR7-1 protein specific antibodies and/or antiphosphotyrosine antibodies.

Following expression of nNR7 and/or nNR7-1 in a host cell, nNR7 and/or nNR7-1 protein may be recovered to provide nNR7 and/or nNR7-1 protein in active form. Several nNR7 and/or nNR7-1 protein purification procedures are available and suitable for use. Recombinant nNR7 and/or nNR7-1 protein may be purified from cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography.

Therapeutic or diagnostic compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders. The effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.

The pharmaceutical compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.

The term "chemical derivative" describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the

toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.

Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages. Alternatively,
5 co-administration or sequential administration of other agents may be desirable.

The present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present
10 invention. The compositions containing compounds identified according to this invention as the active ingredient can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed
15 release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known
20 to those of ordinary skill in the pharmaceutical arts.

Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered
25 in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage
30 regimen.

For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents can be administered concurrently, or they each can be administered at separately staggered times.

35 The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including

type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the patient; and the particular compound thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.

The following example is provided to illustrate the present invention without, however, limiting the same hereto.

15

EXAMPLE 1:
Isolation and Characterization of a DNA Molecule
Encoding nNR7

DNA fragments encoding DBD regions of androgen receptor (AR; Lubahn, et al., 1988, *Mol. Endocrinol.* 2 (12): 1265-1275), estrogen receptor b (ERb; Mosselman, et al., 1996, *FEBS Lett.* 392 (1): 49-53), glucocorticoid receptor (GR; Hollenberg, et al., 1985, *Nature* 318: 635-641) and vitamin D receptor (VDR; Baker, et al., 1988, *Proc. Natl. Acad. Sci. (U.S.A.)* 85 (10): 3294-3298) were generated by PCR made from human fetal brain mRNA for AR, ERb and Grand human small intestine mRNA for VDR. These cDNA fragments were subcloned into pCR cloning vectors as described by the manufacturer. The following oligonucleotide primers were utilized to generate fragments the above-mentioned cDNA fragments for plasmid subcloning:

- | | | | |
|----|----|-------|---|
| 30 | 1. | GR-R | 5'-TTTCGAGCTTCCAGGTTCAT-3' (SEQ ID NO: 9) |
| | 2. | GR-F | 5'-CTCCCAAACCTCTGCCTGGTG-3' (SEQ ID NO: 10) |
| | 3. | ERB-R | 5'-CGGGAGCCACACTTCACCAT-3' (SEQ ID NO: 11) |
| | 4. | ERB-F | 5'-GCTCACTTCTGCGCTGTCTG-3' (SEQ ID NO: 12) |
| | 5. | AR-R | 5'-TTCCGGGCTCCCAGAGTCAT-3' (SEQ ID NO: 13) |
| 35 | 6. | AR-F | 5'-CAGAAGACCTGCCTGATCTG-3' (SEQ ID NO: 14) |
| | 7. | VDR-R | 5'-GAAATGAACTCCTTCATCAT-3' (SEQ ID NO: 15) |
| | 8. | VDR-F | 5'-CCGGATCTGTGGGGTGTGTG-3' (SEQ ID NO: 16). |

The DNA fragments were purified using a Qiagen gel extraction kit. Phosphorylation, self-ligation and transformation of the purified DNA was carried out as recommended by the manufacturer.

- These DBD probes were utilized to screen a mixed cDNA library.
- 5 from adrenal, bone marrow, brain, fetal brain, heart, fetal kidney, liver, fetal liver, lung, fetal lung, mammary gland, pancreas, placenta, prostate, skeletal muscle, small intestine, spleen, testis, thyroid, thymus, and uterus tissue. The probes used in the screening were DNA fragments corresponding to AR, ERb, GR and VDR DNA binding
- 10 domain regions and 250,000 primary clones from the mixed library were screened. After two rounds of screening, *in vivo* excision was carried out on the purified lZAPII phages which showed positive signals at low stringency condition. Plasmid DNA samples were submitted to
- 15 sequence directly using M13 forward and reverse primers. Blast search of the sequence information obtained was done using computer program PhredPhrap. Clone gm6 was found to be a novel receptor. DNA sequencing was continued from both 5' and 3' ends on nNR7. An intron was identified when sequencing with pgm6y2
- 20 (5'-CTTCAATGTCATGACATG-3'; SEQ ID NO; 3). A cDNA fragment flanking the intron region was retrieved via PCR using primer pair of NR7F (5'-CCAAATCTGCCGTGTATGTG-3'; SEQ ID NO; 4) and pgm6xC (5'-GTCAGTGCACTCTCCACGT-3'; SEQ ID NO; 5) followed by double nested primers of pgm6y2 and pgm6xD
- 25 (5'-TGCAGCTGGTCCACCACGCG-3'; SEQ ID NO; 6). A prominent DNA fragment of ~1.5 kb was amplified from testis and brain cDNAs. The fragment was purified and subcloned into pCRII vector (Invitrogen, San Diego, CA). Automated sequencing was performed on several of the clones. Sequence assembly and analysis were performed with
- 30 Ambiguities and/or discrepancies between automated base calling in sequencing reads were visually examined and edited to the correct base call. The final nucleotide sequence encoding nNR7 is shown as set forth in Figure 1A-C and as set forth as SEQ ID NO: 1. The complete sequencing of the gm6 clone revealed a 3.1 kb cDNA which codes an
- 35 authentic novel nuclear receptor. Primer pair pgm6xAR (5'-GGGTATGCTCTGTGACAAG-3'; SEQ ID NO; 7) and pgm6x

(5'-AGGCAGGCACTTTTCATACC-3'; SEQ ID NO: 8) in the 3' non-coding region were used to scan the 83 clones of the Stanford radiation hybrid panel (Cox et al., 1990, *Science*, 250:245-250). The PCR results were scored and submitted to the Stanford Genome Center for linkage analysis. The result indicated that nNR7 was located on chromosome 3. Northern analysis on Clontech blots showed that nNR7 was mainly expressed in human liver at medium to low levels. The liver is the principal site to convert inert forms of D vitamin to active forms which are transported to target tissues, such as intestine, to activate VDR. nNR7 expressed in the liver may be activated by one of the vitamin D metabolites and perform other biological functions of D vitamins. In addition, as discussed herein, nNR7 is involved in regulation a CYP3A4.

EXAMPLE 2:
Isolation and Characterization of a DNA Molecule
Encoding nNR7-1

As disclosed within the specification, the human nNR7 cDNA does not contain a starting Met. Therefore, efforts were made to extend the nNR7 5'-end sequence. Three of the clones from 5'-end RACE (rapid amplification of cDNA end) showed divergence from the original one. One clone contains a starting Met with an inframe stop codon in front. This cDNA clone, nNR7-1, represents a complete open reading frame (ORF) for a human NR7-1 receptor protein.

Oligonucleotide 5'-AAG CCC TTG CAT CCT TCA CA-3' (SEQ ID NO:19) was paired with primer AP1 5'-CCA TCC TAA TAC GAC TCA CTA TAG GGC-3' SEQ ID NO:20; Clontech, Palo Alto, CA) to amplify nNR7 5' cDNA ends. The template used was human liver Marathon-Ready™ cDNA from Clontech. DNA product from one round of PCR reaction was gel purified using Qiagen gel extraction kit (Chatsworth, CA). The DNA fragment was then subcloned into PCRITM TA vector (Invitrogen, Carlsbad, CA). Plasmid DNA from multiple clones were prepared and submitted for sequencing using the ABI PRISM™ dye terminator cycle sequencing ready reaction kit with AmpliTaq DNA polymerase, FS (Perkin Elmer, Norwalk, CT). The sequencing primers used were: TAF 5'-GTA CCG AGC TCG GAT CCA CTA-3' (SEQ ID

NO: 21, TAR 5'-CCG CCA GTG TGA TGG ATA TCT-3' (SEQ ID NO:22)
R7LA 5'-CTC ATC TGC GTT GAC ACT GGG-3' (SEQ ID NO:23).

Sequence assembly and analysis were performed with
SEQUENCHERTM 3.0 (Gene Codes Corporation, Ann Arbor, MI).

- 5 Ambiguities and/or discrepancies between automated base calling in
sequencing reads were visually examined and edited to the correct base
call. Clone 6.2 (referred herein as clone nNR7-1) results in a different
open reading frame from the original one but with an in-frame Met and
upstream stop codon. The site of divergence between SEQ ID NO:1 and
10 SEQ ID NO:17 (as discussed in the Detailed Description of the Invention)
is the same as for clone F1 and A2, the other two clones derived from
this 5'-RACE experiment. Therefore, it is likely that the cDNA clone
which encodes nNR7 (SEQ ID NOs: 1 and 2) is a partially processed
cDNA while clone 6.2 (nNR7-1; SEQ ID NOs: 1 and 2) is a completely
15 processed cDNA. As noted in Example 1 for nNR7-1, nNR7-1 is located
on chromosome 3, near the 3q13.2 locus. The nNR7-1 clone is expressed
in human liver at medium to low levels and within the small intestine.
As noted throughout this specification, nNR7-1 will be useful in assays
to identify compounds which modulate CYP3A4 expression as well as
20 possible interactions within Vitamin D metabolism.

WHAT IS CLAIMED:

1. A purified DNA molecule encoding a human nNR7 protein wherein said protein comprises the amino acid sequence as follows:

SILCTGLFKV DPRGEVGAKN LPPSSPRGPE ANLEVRPKES WNHADVFHCE
DTESVPGKPS VNADEEVGGP QICRVCGDKA TGYHFNVMTC EGCKGFFRRA
MKRNARLRCP FRKGACEITR KTRRQCQACR LRKCLESGBK KEMIMSDEAV
EERRALIKRK KSERTGTQPL GVQGLTEEQR MMIRELMDAQ MKTFDITTFSH
10 FKNFRLPGVL SSGCELPESL QAPSREEAAK WSQVRKDLCS LKVSLLQLRGE
DGSVWNYKPP ADSSGKEIFS LLPHMADMST YMFKGIISFA KVISYFRDLP
IEDQISLLKG AAFELCQLRF NTVFNAETGT WECGRLSYCL EDTAGGFQQL
LLEPMLKFHY MLKKLQLHEE EYVLMQAISL FSPDRPGVLQ HRVVDQLQEQ
FAITLKSYIE CNRPQPAHRF LFLKIMAMLT ELRSINAQHT QRLLRIQDIH
15 PFATPLMQEL FGITGS, as set forth in three-letter
abbreviation in SEQ ID NO: 2.

2. An expression vector for expressing a human nNR7 protein in a recombinant host cell wherein said expression vector comprises a DNA molecule of claim 1.

3. A host cell which expresses a recombinant human nNR7 protein wherein said host cell contains the expression vector of claim 2.

4. A process for expressing a human nNR7 protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 2 into a suitable host cell; and,

(b) culturing the host cells of step (a) under conditions which allow expression of said the human nNR7 protein from said expression vector.

35

5. A purified DNA molecule encoding a human nNR7 protein wherein said protein consists of the amino acid sequence as follows:

5 SILCTGLFKV DPRGEVGAKN LPPSSPRGPE ANLEVRPKES WNHADVFHCE
 DTESVPGKPS VNADEEVGGP QICRVCGDKA TGYHFNVMTC EGCKGFFRRA
 MKRNARLRCP FRKGACEITR KTRRQCQACR LKRCLESGMK KEMIMSDEAV
 EERRALIKRK KSERTGTQPL GVQGLTEEQR MMIRELMDAQ MKTFDITTFSH
 FKNFRLPGVL SSGCELPESL QAPSREEAAK WSQVRKDLCS LKVSLLQLRGE
 DGSVWNYKPP ADGGGKEIFS LLPHMADMST YMFKGIISFA KVISYFRDLP
 10 IEDQISLLKG AAFELCQLRF NTVFNAETGT WECGRLSYCL EDTAGGFQQL
 LLEPMLKFHY MLKKLQLHEE EYVLMQAISL FSPDRPGVLQ HRVVDQLQEQ
 FAITLKSYLE CNRPQPAHRF LFLKIMAMLT ELRSINAQHT QRLRLIQDIH
 PFATPLMQEL FGITGS, as set forth in three-letter abbreviation in
 SEQ ID NO: 2.

15

6. An expression vector for expressing a human nNR7 protein in a recombinant host cell wherein said expression vector comprises a DNA molecule of claim 5.

20

7. A host cell which expresses a recombinant human nNR7 protein wherein said host cell contains the expression vector of claim 6.

25

8. A process for expressing a human nNR7 protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 6 into a suitable host cell; and,

30

(b) culturing the host cells of step (a) under conditions which allow expression of said the human nNR7 protein from said expression vector.

35

9. A purified DNA molecule encoding a human nNR7 protein wherein said DNA molecule consists of the nucleotide sequence as set forth in SEQ ID NO: 1, as follows:

TACGCCAAGC TCGAAATTAA CCCTCACTAA AGGGAACAAA AGCTGGAGCT
CCACCGCGGT GGCGGCCGCT CTAGAACTAG TGGATCCCCC GGGCTGCAGG
AATTCGAATT CTCATAACCT ATGACTAGGA CGGGAAGAGG AAGCACTGCC
TTTACTTCAG TGGGAATCTC GGCCTCAGCC TGCAAGCCAA GTGTTCACAG
5 TGAGAAAAGC AAGAGAATAA GCTAATACTC CTGTCCTGAA CAAGGCAGCG
GCTCCTTGGT AAAGCTACTC CTTGATCGAT CCTTTGCACC GGATTGTTCA
AAGTGGACCC CAGGGGAGAA GTCGGAGCAA AGAACTTACC ACCAAGCAGT
CCAAGAGGCC CAGAAGCAAA CCTGGAGGTG AGACCCAAAG AAAGCTGGAA
CCATGCTGAC TTTGTACACT GTGAGGACAC AGAGTCTGTT CCTGGAAAGC
10 CCAGTGTCAG CGCAGATGAG GAAGTCGGAG GTCCCCAAAT CTGCCGTGTA
TGTGGGGACA AGGCCACTGG CTATCACTTC AATGTCATGA CATGTGAAGG
ATGCAAGGGC TTTTTCAGGA GGGCCATGAA ACGCAACGCC CGGCTGAGGT
GCCCCTTCCG GAAGGGCGCC TGCAGATCA CCCGGAAGAC CCGGCGACAG
TGCCAGGCCT GCCGCCTGCG CAAGTGCCTG GAGAGCGGCA TGAAGAAGGA
15 GATGATCATG TCCGACGAGG CCGTGGAGGA GAGGCGGGCC TTGATCAAGC
GGAAGAAAAG TGAACGGACA GGGACTCAGC CACTGGGAGT GCAGGGGCTG
ACAGAGGAGC AGCGGATGAT GATCAGGGAG CTGATGGACG CTCAGATGAA
AACCTTTGAC ACTACCTTCT CCCATTTCAG GAATTTCCGG CTGCCAGGGG
TGCTTAGCAG TGGCTGCGAG TTGCCAGAGT CTCTGCAGGC CCCATCGAGG
20 GAAGAAGCTG CCAAGTGGAG CCAGGTCCGG AAAGATCTGT GCTCTTTGAA
GGTCTCTCTG CAGCTGCGGG GGGAGGATGG CAGTGTCTGG AACTACAAAC
CCCCAGCCGA CAGTGGCGGG AAAGAGATCT TCTCCCTGCT GCCCCACATG
GCTGACATGT CAACCTACAT GTTCAAAGGC ATCATCAGCT TTGCCAAAGT
CATCTCCTAC TTCAGGGACT TGCCCATCGA GGACCAGATC TCCCTGCTGA
25 AGGGGGCCGC TTTTCGAGCTG TGTCAACTGA GATTCAACAC AGTGTTC AAC
GCGGAGACTG GAACCTGGGA GTGTGGCCGG CTGTCTACT GCTTGGAAGA
CACTGCAGGT GGCTTCCAGC AACTTCTACT GGAGCCCATG CTGAAATTCC
ACTACATGCT GAAGAAGCTG CAGCTGCATG AGGAGGAGTA TGTGCTGATG
CAGGCCATCT CCCTCTTCTC CCCAGACCGC CCAGGTGTGC TGCAGCACCG
30 CGTGGTGGAC CAGCTGCAGG AGCAATTTCG CATTACTCTG AAGTCCTACA
TTGAATGCAA TCGGCCCCAG CCTGCTCATA GGTTCCTTGT CCTGAAGATC
ATGGCTATGC TCACCGAGCT CCGCAGCATC AATGCTCAGC ACACCCAGCG
GCTGCTGCGC ATCCAGGACA TACACCCCTT TGCTACGCCC CTCATGCAGG
AGTTGTTTCGG CATCACAGGT AGCTGAGCGG CTGCCCTTGG GTGACACCTC
35 CGAGAGGCAG CCAGACCCAG AGCCCTCTGA GCCGCCACTC CCGGGCCAAG
ACAGATGGAC ACTGCCAAGA GCCGACAATG CCCTGCTGGC CTGTCTCCCT

```

AGGGAATTCC TGCTATGACA GCTGGCTAGC ATTCCTCAGG AAGGACATGG
GTGCCCCCCA CCCCAGTTC AGTCTGTAGG GAGTGAAGCC ACAGATTCTT
ACGTGGAGAG TGCAC TGACC TG TAGGTCAG GACCATCAGA GAGGCAAGGT
TGCCCTTTCC TTTTAAAAGG CCCTGTGGTC TGGGGAGAAA TCCCTCAGAT
5 CCCACTAAAG TGTCAAGGTG TGGAAGGGAC CAAGCGACCA AGGATAGGCC
ATCTGGGGTC TATGCCACA TACCCACGTT TGTTCGCTTC CTGAGTCTTT
TCATTGCTAC CTCTAATAGT CCTGTCTCCC ACTTCCCACT CGTTCCCCTC
CTCTTCCGAG CTGCTTTGTG GGCTCCAGGC CTGTACTCAT CGGCAGGTGC
ATGAGTATCT GTGGGAGTCC TCTAGAGAGA TGAGAAGCCA GGAGGCCTGC
10 ACCAAATGTC AGAAGCTTGG CATGACCTCA TTCCGGCCAC ATCATTCTGT
GTCTCTGCAT CCATTTGAAC ACATTATTAA GCACCGATAA TAGGTAGCCT
GCTGTGGGGT ATACAGCATT GACTCAGATA TAGATCCTGA GCTCACAGAG
TTTATAGTTA AAAAAACAAA CAGAAACACA AACAATTTGG ATCAAAAGGA
GAAATGATAA GTGACAAAAG CAGCACAAGG AATTTCCCTG TGTGGATGCT
15 GAGCTGTGAT GCGGGGCACT GGGTACCCAA GTGAAGGTTC CCGAGGACAT
GAGTCTGTAG GAGCAAGGGC ACAAAC TGCA GCTGTGAGTG CGTGTGTGTG
ATTTGGTGTA GGTAGGTCTG TTTGCCACTT GATGGGGCCT GGGTTTGTTC
CTGGGGCTGG AATGCTGGGT ATGCTCTGTG ACAAGGCTAC GCTGACAATC
AGTTAAACAC ACCGGAGAAG AACCATT TAC ATGCACCTTA TATTTCTGTG
20 TACACATCTA TTCTCAAAGC TAAAGGGTAT GAAAGTGCCT GCCTTGTTTTA
TAGCCACTTG TGAGTAAAAA TTTTTTTGCA TTTTCACAAA TTATACTTTA
TATAAGGCAT TCCACACCTA AGAACTAGTT TTGGGAAATG TAGCCCTGGG
TTTAATGTCA AATCAAGGCA AAAGGAATTA AATAATGTAC TTTTGGCTAG
AGGGGTAAAC TTTTTTG GCC TTTTCTGGG GAAAATAATG TGGGGGTGTG
25 GGAATTCGAA TTCGATATCA AGCTTATCGA TACCGTCGAC CTCGAGGGGG
GGCCCGGTAC CCAATTCGCC CTATAGTGAG TCGTATTACA ATT
(SEQ ID NO: 1).

```

10. A DNA molecule of claim 9 which consists of
 30 nucleotide 276 to about nucleotide 1676 of SEQ ID NO: 1.

11. An expression vector for expressing a human nNR7
 protein wherein said expression vector comprises a DNA molecule of
 claim 9.
 35

12. An expression vector for expressing a human nNR7 protein wherein said expression vector comprises a DNA molecule of claim 10.

5 13. A host cell which expresses a recombinant human nNR7 protein wherein said host cell contains the expression vector of claim 11.

10 14. A host cell which expresses a recombinant human nNR7 protein wherein said host cell contains the expression vector of claim 12.

15 15. A process for expressing a human nNR7 protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 11 into a suitable host cell; and,

20 (b) culturing the host cells of step (a) under conditions which allow expression of said the human nNR7 protein from said

25 16. A purified human nNR7 protein which comprises the amino acid sequence as set forth in SEQ ID NO:2.

17. A purified human nNR7 protein of claim 16 which consists of the amino acid sequence as set forth in SEQ ID NO:2.

30 18. A method for determining whether a substance is capable of binding to nNR7 comprising:

(a) providing test cells by transfecting cells with an expression vector that directs the expression of nNR7 in the cells;
(b) exposing the test cells to the substance;
(c) measuring the amount of binding of the substance to
35 nNR7;

(d) comparing the amount of binding of the substance to nNR7 in the test cells with the amount of binding of the substance to control cells that have not been transfected with nNR7.

5 19. A method of determining whether a substance acts as a modulator of nNR7 activity which comprises:

- (a) providing test cells by transfecting cells with a receptor expression vector that directs the expression of nNR7 in the cells;
- 10 (b) providing test cells by transfecting the cells of step (a) with a second reporter expression vector that directs expression of a reporter gene under control of a regulatory element which is responsive to nNR7
- (b) exposing the test cells to the substance;
- 15 (c) measuring the amount of binding of expression of the reporter gene;
- (d) comparing the amount of expression of the reporter gene in the test cells with the amount of expression of the reporter gene in control cells that has been transfected with a reporter vector of step (b)
- 20 but not a receptor vector of step (a).

20. A purified DNA molecule encoding a human nNR7 protein wherein said protein comprises the amino acid sequence as follows:

25 MTVTRTHHFK EGSLRAPAIP LHSAAELAS NHPRGPEANL EVRPKESWNH
 ADFVHCEDTE SVPGKPSVNA DEEVGGPQIC RVC GDKATGY HFNVMTCEGC
 KGFFRRAMKR NARLRC PFRK GACEITRKTR RQCQACRLRK CLESGMKKEM
 IMSDEAVEER RALIKRKKSE RTGTQPLGVQ GLTEEQRMMI RELMDAQMKT
 FDTTFSHFKN FRLPGVLSSG CELPESLQAP SREEAAKWSQ VRKDLCSLKV
 30 SLQLRGEDGS VWNYPKPPADS GGKEIFSLLP HMA DMSTYMF KGIISFAKVI
 SYFRDLPIED QISLLKGA AF ELCQLRFNTV FNAETGTWEC GRLSYCLEDT
 AGGFQQLLLE PMLKFHYMLK KLQLHEEEYV LMQAISLFSP DRPGVLQHRV
 VDQLQE QFAI TLKSYIECNR PQPAHRFLFL KIMAMLTEL R SINAQHTQRL
 LRIQDIHPFA TPLMQELFGI TGS, as set forth in the three-letter
 35 abbreviation in SEQ ID NO: 18.

21. An expression vector for expressing a human nNR7-1 protein in a recombinant host cell wherein said expression vector comprises a DNA molecule of claim 20.

5 22. A host cell which expresses a recombinant human nNR7-1 protein wherein said host cell contains the expression vector of claim 21.

10 23. A process for expressing a human nNR7-1 protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 21 into a suitable host cell; and,

15 (b) culturing the host cells of step (a) under conditions which allow expression of said the human nNR7-1 protein from said expression vector.

20 24. A purified DNA molecule encoding a human nNR7-1 protein wherein said protein consists of the amino acid sequence as follows:

MTVTRTHHFK EGSLRAPAIP LHSAAAE LAS NHPRGPEANL EVRPKESWNH
ADFDVHCEDTE SVPGKPSVNA DEEVGGPQIC RVC GDKATGY HFNVMTCEGC
KGFFRRAMKR NARLRCPFRK GACEITRKTR RQCQACRLRK CLESGMKKEM
25 IMSDEAVEER RALIKRKKSE RTGTQPLGVQ GLTEEQRMMI RELMDAQMKT
FDTTFSHFKN FRLPGVLSSG CELPESLQAP SREEAAKWSQ VRKDLC SLKV
SLQLRGEDGS VWNYPKPPADS GGKEIFSLLP HMADMSTYMF KGIISFAKVI
SYFRDLPIED QISLLKGA AF ELCQLRFNTV FNAETGTWEC GRLSYCLEDT
AGGFQQLLLE PMLKFHYMLK KLQLHEEEYV LMQAISLFSP DRPGVLQHRV
30 VDQLQE QFAI TLKSYIECNR PQPAHRFLFL KIMAMLTCLR SINAQHTQRL
LRIQDIHPFA TPLMQELFGI TGS, as set forth in the three-letter
abbreviation in SEQ ID NO: 18.

35 25. An expression vector for expressing a human nNR7-1 protein in a recombinant host cell wherein said expression vector comprises a DNA molecule of claim 24.

26. A host cell which expresses a recombinant human nNR7-1 protein wherein said host cell contains the expression vector of claim 25.

5

27. A process for expressing a human nNR7-1 protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 25 into a suitable host cell; and,

10

(b) culturing the host cells of step (a) under conditions which allow expression of said the human nNR7-1 protein from said expression vector.

15

28. A purified DNA molecule encoding a human nNR7-1 protein wherein said DNA molecule consists of the nucleotide sequence as set forth in SEQ ID NO: 17, as follows:

20 TCCATCCTAA TACGACTCAC TATAGGGCTC GAGCGGCCGC CCGGGCAGGT
CTTTTGGCCT GCTGGGTTAG TGCTGGCAGC CCCCTGAGGC CAAGGACAGC
AGCATGACAG TCACCAGGAC TCACCACTTC AAGGAGGGGT CCCTCAGAGC
ACCTGCCATA CCCCTGCACA GTGCTGCGGC TGAGTTGGCT TCAAACCATC
CAAGAGGCCC AGAAGCAAAC CTGGAGGTGA GACCCAAAGA AAGCTGGAAC
CATGCTGACT TTGTACACTG TGAGGACACA GAGTCTGTTC CTGGAAGGCC
25 CAGTGTCAAC GCAGATGAGG AAGTCGGAGG TCCCCAAATC TGCCGTGTAT
GTGGGGACAA GGCCACTGGC TATCACTTCA ATGTCATGAC ATGTGAAGGA
TGCAAGGGCT TTTTCAGGAG GGCCATGAAA CGCAACGCCC GGCTGAGGTG
CCCCTTCCGG AAGGGCGCCT GCGAGATCAC CCGGAAGACC CGGCGACAGT
GCCAGGCCTG CCGCCTGCGC AAGTGCCTGG AGAGCGGCAT GAAGAAGGAG
30 ATGATCATGT CCGACGAGGC CGTGGAGGAG AGGCGGGCCT TGATCAAGCG
GAAGAAAAGT GAACGGACAG GGA CTCAGCC ACTGGGAGTG CAGGGGCTGA
CAGAGGAGCA GCGGATGATG ATCAGGGAGC TGATGGACGC TCAGATGAAA
ACCTTTGACA CTACCTTCTC CCATTTC AAG AATTTC CGGC TGCCAGGGGT
GCTTAGCAGT GGCTGCGAGT TGCCAGAGTC TCTGCAGGCC CCATCGAGGG
35 AAGAAGCTGC CAAGTGGAGC CAGGTCCGGA AAGATCTGTG CTCTTTGAAG
GTCTCTCTGC AGCTGCGGGG GGAGGATGGC AGTGTCTGGA ACTACAAACC

	CCCAGCCGAC	AGTGGCGGGA	AAGAGATCTT	CTCCCTGCTG	CCCCACATGG
	CTGACATGTC	AACCTACATG	TTCAAAGGCA	TCATCAGCTT	TGCCAAAGTC
	ATCTCCTACT	TCAGGGACTT	GCCCATCGAG	GACCAGATCT	CCCTGCTGAA
	GGGGGCCGCT	TTCGAGCTGT	GTCAACTGAG	ATTCAACACA	GTGTTCAACG
5	CGGAGACTGG	AACCTGGGAG	TGTGGCCGGC	TGTCCTACTG	CTTGGAAGAC
	ACTGCAGGTG	GCTTCCAGCA	ACTTCTACTG	GAGCCCATGC	TGAAATTCCA
	CTACATGCTG	AAGAAGCTGC	AGCTGCATGA	GGAGGAGTAT	GTGCTGATGC
	AGGCCATCTC	CCTCTTCTCC	CCAGACCGCC	CAGGTGTGCT	GCAGCACCGC
	GTGGTGACC	AGCTGCAGGA	GCAATTCGCC	ATTACTCTGA	AGTCCTACAT
10	TGAATGCAAT	CGGCCCCAGC	CTGCTCATAG	GTTCTTGTTT	CTGAAGATCA
	TGGCTATGCT	CACCGAGCTC	CGCAGCATCA	ATGCTCAGCA	CACCCAGCGG
	CTGCTGCGCA	TCCAGGACAT	ACACCCCTTT	GCTACGCCCC	TCATGCAGGA
	GTTGTTTCGGC	ATCACAGGTA	GCTGAGCGGC	TGCCCTTGGG	TGACACCTCC
	GAGAGGCAGC	CAGACCCAGA	GCCCTCTGAG	CCGCCACTCC	CGGGCCAAGA
15	CAGATGGACA	CTGCCAAGAG	CCGACAATGC	CCTGCTGGCC	TGTCTCCCTA
	GGGAATTCCCT	GCTATGACAG	CTGGCTAGCA	TTCCTCAGGA	AGGACATGGG
	TGCCCCCACC	CCCCAGTTCA	GTCTGTAGGG	AGTGAAGCCA	CAGATTCTTA
	CGTGGAGAGT	GCACTGACCT	GTAGGTCAGG	ACCATCAGAG	AGGCAAGGTT
	GCCCTTTTCCT	TTTAAAAGGC	CCTGTGGTCT	GGGGAGAAAT	CCCTCAGATC
20	CCACTAAAGT	GTCAAGGTGT	GGAAGGGACC	AAGCGACCAA	GGATAGGCCA
	TCTGGGGTCT	ATGCCCACAT	ACCCACGTTT	GTTGCTTCC	TGAGTCTTTT
	CATTGCTACC	TCTAATAGTC	CTGTCTCCCA	CTTCCCACTC	GTTCCCTCC
	TCTTCCGAGC	TGCTTTGTGG	GCTCCAGGCC	TGTACTCATC	GGCAGGTGCA
	TGAGTATCTG	TGGGAGTCCT	CTAGAGAGAT	GAGAAGCCAG	GAGGCCTGCA
25	CCAAATGTCA	GAAGCTTGGC	ATGACCTCAT	TCCGGCCACA	TCATTCTGTG
	TCTCTGCATC	CATTTGAACA	CATTATTAAG	CACCGATAAT	AGGTAGCCTG
	CTGTGGGGTA	TACAGCATTG	ACTCAGATAT	AGATCCTGAG	CTCACAGAGT
	TTATAGTTAA	AAAAACAAAC	AGAAACACAA	ACAATTGGA	TCAAAAGGAG
	AAATGATAAG	TGACAAAAGC	AGCACAAGGA	ATTTCCCTGT	GTGGATGCTG
30	AGCTGTGATG	GCGGGCACTG	GGTACCCAAG	TGAAGGTTCC	CGAGGACATG
	AGTCTGTAGG	AGCAAGGGCA	CAAACGTCAG	CTGTGAGTGC	GTGTGTGTGA
	TTTGGTGTAG	GTAGGTCTGT	TTGCCACTTG	ATGGGGCCTG	GGTTTGTTC
	TGGGGCTGGA	ATGCTGGGTA	TGCTCTGTGA	CAAGGCTACG	CTGACAATCA
	GTAAACACA	CCGGAGAAGA	ACCATTTACA	TGCACCTTAT	ATTTCTGTGT
35	ACACATCTAT	TCTCAAAGCT	AAAGGGTATG	AAAGTGCCTG	CCTTGTTTAT
	AGCCACTTGT	GAGTAAAAAT	TTTTTTGCAT	TTTCACAAAT	TATACTTTAT

ATAAGGCATT CCACACCTAA GAACTAGTTT TGGGAAATGT AGCCCTGGGT
TTAATGTCAA ATCAAGGCAA AAGGAATTAA ATAATGTACT TTTGGCTAGA
GGGGTAAACT TTTTGGCCT TTTTCTGGGG AAAATAATGT GGGGGTGTGG
(SEQ ID NO: 17).

5

29. A DNA molecule of claim 28 which consists of nucleotide 104 to about nucleotide 1525 of SEQ ID NO: 17.

30. An expression vector for expressing a human nNR7-1 protein wherein said expression vector comprises a DNA molecule of claim 28.

31. An expression vector for expressing a human nNR7-1 protein wherein said expression vector comprises a DNA molecule of claim 29.

32. A host cell which expresses a recombinant human nNR7-1 protein wherein said host cell contains the expression vector of claim 30.

20

33. A host cell which expresses a recombinant human nNR7-1 protein wherein said host cell contains the expression vector of claim 31.

34. A process for expressing a human nNR7 protein in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 29 into a suitable host cell; and,

30

(b) culturing the host cells of step (a) under conditions which allow expression of said the human nNR7-1 protein from said expression vector.

35. A purified human nNR7-1 protein which comprises the amino acid sequence as set forth in SEQ ID NO:18.

5 36. A purified human nNR7-1 protein of claim 35 which consists of the amino acid sequence as set forth in SEQ ID NO:18.

37. A method for determining whether a substance is capable of binding to nNR7-1 comprising:

- 10 (a) providing test cells by transfecting cells with an expression vector that directs the expression of nNR7-1 in the cells;
- (b) exposing the test cells to the substance;
- (c) measuring the amount of binding of the substance to nNR7-1;
- 15 (d) comparing the amount of binding of the substance to nNR7-1 in the test cells with the amount of binding of the substance to control cells that have not been transfected with nNR7-1.

38. A method of determining whether a substance acts as a modulator of nNR7-1 activity which comprises:

- 20 (a) providing test cells by transfecting cells with a receptor expression vector that directs the expression of nNR7-1 in the cells;
- (b) providing test cells by transfecting the cells of step (a)
- 25 with a second reporter expression vector that directs expression of a reporter gene under control of a regulatory element which is responsive to nNR7-1
- (b) exposing the test cells to the substance;
- (c) measuring the amount of binding of expression of the
- 30 reporter gene;
- (d) comparing the amount of expression of the reporter gene in the test cells with the amount of expression of the reporter gene in control cells that has been transfected with a reporter vector of step (b) but not a receptor vector of step (a).

35

1/14

TACGCCAAGC TCGAAATTAA CCCTCACTAA AGGGAACAAA AGCTGGAGCT
CCACCGCGGT GCGGGCCGCT CTAGAACTAG TGGATCCCC GGGCTGCAGG
AATTCGAATT CTCATAACCT ATGACTAGGA CGGGAAGAGG AAGCACTGCC
TTTACTTCAG TGGGAATCTC GGCCTCAGCC TGCAAGCCAA GTGTTACAG
TGAGAAAAGC AAGAGAATAA GCTAATACTC CTGTCCTGAA CAAGGCAGCG
GCTCCTTGGT AAAGCTACTC CTTGATCGAT CCTTTGCACC GGATTGTTCA
AAGTGGACCC CAGGGGAGAA GTCGGAGCAA AGAACTTACC ACCAAGCAGT
CCAAGAGGCC CAGAAGCAAA CCTGGAGGTG AGACCCAAAG AAAGCTGGAA
CCATGCTGAC TTTGTACACT GTGAGGACAC AGAGTCTGTT CCTGGAAAGC
CCAGTGTCAG CGCAGATGAG GAAGTCGGAG GTCCCCAAAT CTGCCGTGTA
TGTGGGGACA AGGCCACTGG CTATCACTTC AATGTCATGA CATGTGAAGG
ATGCAAGGGC TTTTTCAGGA GGGCCATGAA ACGCAACGCC CGGCTGAGGT
GCCCCTTCCG GAAGGGCGCC TGCAGATCA CCCGGAAGAC CCGGCGACAG
TGCCAGGCCT GCCGCCTGCG CAAGTGCTG GAGAGCGGCA TGAAGAAGGA
GATGATCATG TCCGACGAGG CCGTGGAGGA GAGGCGGGCC TTGATCAAGC
GGAAGAAAAG TGAACGGACA GGGACTCAGC CACTGGGAGT GCAGGGGCTG
ACAGAGGAGC AGCGGATGAT GATCAGGGAG CTGATGGACG CTCAGATGAA
AACCTTTGAC ACTACCTTCT CCCATTTCAA GAATTTCCGG CTGCCAGGGG
TGCTTAGCAG TGGCTGCGAG TTGCCAGAGT CTCTGCAGGC CCCATCGAGG
GAAGAAGCTG CCAAGTGGAG CCAGGTCCGG AAAGATCTGT GCTCTTTGAA
GGTCTCTCTG CAGCTGCGGG GGGAGGATGG CAGTGTCTGG AACTACAAAC
CCCCAGCCGA CAGTGGCGGG AAAGAGATCT TCTCCCTGCT GCCCCACATG
GCTGACATGT CAACCTACAT GTTCAAAGGC ATCATCAGCT TTGCCAAAGT
CATCTCCTAC TTCAGGGACT TGCCCATCGA GGACCAGATC TCCCTGCTGA

FIG. 1A

SUBSTITUTE SHEET (RULE 26)

2/14

AGGGGGCCGC TTTCGAGCTG TGTCAACTGA GATTCAACAC AGTGTTCAAC
GCGGAGACTG GAACCTGGGA GTGTGGCCGG CTGTCCTACT GCTTGGAAGA
CACTGCAGGT GGCTTCCAGC AACTTCTACT GGAGCCCATG CTGAAATTCC
ACTACATGCT GAAGAAGCTG CAGCTGCATG AGGAGGAGTA TGTGCTGATG
CAGGCCATCT CCCTCTTCTC CCCAGACCGC CCAGGTGTGC TGCAGCACCG
CGTGGTGGAC CAGCTGCAGG AGCAATTGCG CATTACTCTG AAGTCCTACA
TTGAATGCAA TCGGCCCCAG CCTGCTCATA GGTCTTGTT CCTGAAGATC
ATGGCTATGC TCACCGAGCT CCGCAGCATC AATGCTCAGC ACACCCAGCG
GCTGCTGCGC ATCCAGGACA TACACCCCTT TGCTACGCCC CTCATGCAGG
AGTTGTTGCG CATCACAGGT AGCTGAGCGG CTGCCCTTGG GTGACACCTC
CGAGAGGCAG CCAGACCCAG AGCCCTCTGA GCCGCCACTC CCGGGCCAAG
ACAGATGGAC ACTGCCAAGA GCCGACAATG CCCTGCTGGC CTGTCTCCCT
AGGGAATTCC TGCTATGACA GCTGGCTAGC ATTCCTCAGG AAGGACATGG
GTGCCCCCA CCCCCAGTTC AGTCTGTAGG GAGTGAAGCC ACAGATTCTT
ACGTGGAGAG TGCACTGACC TGTAGGTCAG GACCATCAGA GAGGCAAGGT
TGCCCTTTCC TTTTAAAGG CCCTGTGGTC TGGGGAGAAA TCCCTCAGAT
CCCACTAAAG TGTCAAGGTG TGGAAGGGAC CAAGCGACCA AGGATAGGCC
ATCTGGGGTC TATGCCACA TACCCACGTT TGTTGCTTC CTGAGTCTTT
TCATTGCTAC CTCTAATAGT CCTGTCTCCC ACTTCCCACT CGTCCCCCTC
CTCTTCCGAG CTGCTTTGTG GGCTCCAGGC CTGTACTCAT CGGCAGGTGC
ATGAGTATCT GTGGGAGTCC TCTAGAGAGA TGAGAAGCCA GGAGGCCTGC
ACCAAATGTC AGAAGCTTGG CATGACCTCA TTCCGGCCAC ATCATTCTGT
GTCTCTGCAT CCATTTGAAC ACATTATTAA GCACCGATAA TAGGTAGCCT

FIG. 1B

3/14

GCTGTGGGGT ATACAGCATT GACTCAGATA TAGATCCTGA GCTCACAGAG
TTTATAGTTA AAAAAACAAA CAGAAACACA AACAATTTGG ATCAAAAGGA
GAAATGATAA GTGACAAAAG CAGCACAAAG AATTTCCCTG TGTGGATGCT
GAGCTGTGAT GGCGGGCACT GGGTACCCAA GTGAAGGTTT CCGAGGACAT
GAGTCTGTAG GAGCAAGGGC ACAAAGTCA GCTGTGAGTG CGTGTGTGTG
ATTTGGTGTA GGTAGGTCTG TTTGCCACTT GATGGGGCCT GGGTTTGTTC
CTGGGGCTGG AATGCTGGGT ATGCTCTGTG ACAAGGCTAC GCTGACAATC
AGTTAAACAC ACCGGAGAAG AACCATTAC ATGCACCTTA TATTTCTGTG
TACACATCTA TTCTCAAAGC TAAAGGTAT GAAAGTGCCT GCCTTGTTTA
TAGCCACTTG TGAGTAAAAA TTTTTTTGCA TTTTCACAAA TTATACTTTA
TATAAGGCAT TCCACACCTA AGAACTAGTT TTGGGAAATG TAGCCCTGGG
TTTAATGTCA AATCAAGGCA AAAGGAATTA AATAATGTAC TTTTGGCTAG
AGGGGTAAAC TTTTTTGGCC TTTTCTGGG GAAAATAATG TGGGGGTGTG
GGAATTCGAA TTCGATATCA AGCTTATCGA TACCGTCGAC CTCGAGGGGG
GGCCCGGTAC CCAATTCGCC CTATAGTGAG TCGTATTACA ATT (SEQ ID NO:1)

FIG.1C

4/14

1 TACGCCAAGCTCGAAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGT 60
61 GGCGGCCGCTCTAGAACTAGTGGATCCCCGGGCTGCAGGAATTGGAATTCTCATAACCT 120
121 ATGACTAGGACGGGAAGAGGAAGCACTGCCTTTACTTCAGTGGGAATCTCGGCCTCAGCC 180
181 TGCAAGCCAAGTGTTACAGTGAGAAAAGCAAGAGAATAAGCTAATACTCCTGTCCTGAA 240
241 CAAGGCAGCGGCTCCTTGGTAAAGCTACTCCTTGATCGATCCTTGCACCGGATTGTTCA 300
S I L C T G L F K
301 AAGTGGACCCCAGGGGAGAAGTCGGAGCAAAGAACTTACCACCAAGCAGTCCAAGAGGCC 360
V D P R G E V G A K N L P P S S P R G P
361 CAGAAGCAAACCTGGAGGTGAGACCCAAAGAAAGCTGGAACCATGCTGACTTTGTACACT 420
E A N L E V R P K E S W N H A D F V H C
421 GTGAGGACACAGAGTCTGTTCTCTGGAAAGCCCAGTGTCAACGCAGATGAGGAAGTCGGAG 480
E D T E S V P G K P S V N A D E E V G G
481 GTCCCCAAATCTGCCGTGTATGTGGGGACAAGGCCACTGGCTATCACTTCAATGTCATGA 540
P Q I C R V C G D K A T G Y H F N V M T
541 CATGTGAAGGATGCAAGGGCTTTTTTCAGGAGGGCCATGAAACGCAACGCCCGGCTGAGGT 600
C E G C K G F F R R A M K R N A R L R C
601 GCCCCTTCCGGAAGGGCGCCTGCGAGATCACCCGGAAGACCCGGCGACAGTGCCAGGCCT 660
P F R K G A C E I T R K T R R Q C Q A C
661 GCCGCCTGCGCAAGTGCCTGGAGAGCGGCATGAAGAAGGAGATGATCATGTCCGACGAGG 720
R L R K C L E S G M K K E M I M S D E A
721 CCGTGGAGGAGAGGCGGGCCTTGATCAAGCGGAAGAAAAGTGAACGGACAGGGACTCAGC 780
V E E R R A L I K R K K S E R T G T Q P
781 CACTGGGAGTGCAGGGGCTGACAGAGGAGCAGCGGATGATGATCAGGGAGCTGATGGACG 840
L G V Q G L T E E Q R M M I R E L M D A
841 CTCAGATGAAAACCTTTGACACTACCTTCTCCCATTTCAAGAATTTCCGGCTGCCAGGGG 900
Q M K T F D T T F S H F K N F R L P G V
901 TGCTTAGCAGTGGCTGCGAGTTGCCAGAGTCTCTGCAGGCCCATCGAGGGAAGAAGCTG 960
L S S G C E L P E S L Q A P S R E E A A

FIG.2A

SUBSTITUTE SHEET (RULE 26)

5/14

961 CCAAGTGGAGCCAGGTCCGGAAAGATCTGTGCTCTTTGAAGGTCTCTCTGCAGCTGCGGG 1020
K W S Q V R K D L C S L K V S L Q L R G

1021 GGGAGGATGGCAGTGTCTGGAAC TACAAACCCCGACAGTGGCGGGAAAGAGATCT 1080
E D G S V W N Y K P P A D S G G K E I F

1081 TCTCCCTGCTGCCCCACATGGCTGACATGTCAACCTACATGTTCAAAGGCATCATCAGCT 1140
S L L P H M A D M S T Y M F K G I I S F

1141 TTGCCAAAGTCATCTCCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGA 1200
A K V I S Y F R D L P I E D Q I S L L K

1201 AGGGGGCCGCTTTTCGAGCTGTGTCAACTGAGATTCAACACAGTGTTC AACCGGAGACTG 1260
G A A F E L C Q L R F N T V F N A E T G

1261 GAACCTGGGAGTGTGGCCGGCTGTCTACTGCTTGGAAGACACTGCAGGTGGCTTCCAGC 1320
T W E C G R L S Y C L E D T A G G F Q Q

1321 AACTTCTACTGGAGCCCATGCTGAAATTCCACTACATGCTGAAGAAGCTGCAGCTGCATG 1380
L L L E P M L K F H Y M L K K L Q L H E

1381 AGGAGGAGTATGTGCTGATGCAGGCCATCTCCCTCTTCTCCCCAGACCGCCAGGTGTGC 1440
E E Y V L M Q A I S L F S P D R P G V L

1441 TGCAGCACCGCTGGTGGACAGCTGCAGGAGCAATTCGCCATTACTCTGAAGTCCTACA 1500
Q H R V V D Q L Q E Q F A I T L K S Y I

1501 TTGAATGCAATCGGCCCCAGCCTGCTCATAGGTTCTTGTTCTGAAGATCATGGCTATGC 1560
E C N R P Q P A H R F L F L K I M A M L

1561 TCACCGAGCTCCGCAGCATCAATGCTCAGCACACCCAGCGGTGCTGCGCATCCAGGACA 1620
T E L R S I N A Q H T Q R L L R I Q D I

1621 TACACCCCTTTGCTACGCCCTCATGCAGGAGTTGTTCCGCATCACAGGTAGCTGAGCGG 1680
H P F A T P L M Q E L F G I T G S (SEQ ID NO:2)

1681 CTGCCCTTGGGTGACACCTCCGAGAGGCAGCCAGACCCAGAGCCCTCTGAGCCGCCACTC 1740

1741 CCGGGCCAAGACAGATGGACACTGCCAAGAGCCGACAATGCCCTGCTGGCCTGTCTCCCT 1800

FIG.2B

6/14

1801 AGGGAATTCCTGCTATGACAGCTGGCTAGCATTCTCAGGAAGGACATGGGTGCCCCCA 1860
1861 CCCCCAGTTCAGTCTGTAGGGAGTGAAGCCACAGATTCTTACGTGGAGAGTGCCTGACC 1920
1921 TGTAGGTCAGGACCATCAGAGAGGCAAGGTTGCCCTTTCTTTTAAAAGGCCCTGTGGTC 1980
1981 TGGGGAGAAATCCCTCAGATCCCACTAAAGTGTC AAGGTGTGGAAGGGACCAAGCGACCA 2040
2041 AGGATAGGCCATCTGGGGTCTATGCCACATACCCACGTTTGTTGCTTCCTGAGTCTTT 2100
2101 TCATTGCTACCTCTAATAGTCTGTCTCCCACTTCCCACTCGTTCCCCTCCTCTTCGGAG 2160
2161 CTGCTTTGTGGGCTCCAGGCCTGTACTCATCGGCAGGTGCATGAGTATCTGTGGGAGTCC 2220
2221 TCTAGAGAGATGAGAAGCCAGGAGGCCTGCACCAAATGTCAGAAGCTTGGCATGACCTCA 2280
2281 TTCCGGCCACATCATTCTGTGTCTCTGCATCCATTTGAACACATTATTAAGCACCGATAA 2340
2341 TAGGTAGCCTGCTGTGGGGTATACAGCATTGACTCAGATATAGATCCTGAGCTCACAGAG 2400
2401 TTTATAGTTAAAAAACAAACAGAAACACAAACAATTTGGATCAAAGGAGAAATGATAA 2460
2461 GTGACAAAAGCAGCACAAGGAATTTCCCTGTGTGGATGCTGAGCTGTGATGGCGGGCACT 2520
2521 GGGTACCCAAGTGAAGGTTCCCGAGGACATGAGTCTGTAGGAGCAAGGGCACAACTGCA 2580
2581 GCTGTGAGTGCGTGTGTGTGATTTGGTGTAGGTAGGTCTGTTTGCCACTTGATGGGGCCT 2640
2641 GGGTTTGTTCCTGGGGCTGGAATGCTGGGTATGCTCTGTGACAAGGCTACGCTGACAATC 2700
2701 AGTTAAACACACCGGAGAAGAACCATTACATGCACCTTATATTTCTGTGTACACATCTA 2760
2761 TTCTCAAAGCTAAAGGGTATGAAAGTGCCTGCCTTGTTTATAGCCACTTGTGAGTAAAAA 2820
2821 TTTTTTGCATTTTCACAAATTATACTTTATATAAGGCATTCCACACCTAAGAACTAGTT 2880
2881 TTGGGAAATGTAGCCCTGGGTTTAATGTCAAATCAAGGCAAAGGAATTAATAATGTAC 2940
2941 TTTTGGCTAGAGGGGTAACTTTTTTGGCCTTTTCTGGGGAAAATAATGTGGGGGTGTG 3000
3001 GGAATTCGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTAC 3060
3061 CCAATTCGCCCTATAGTGAGTCGTATTACAATT (SEQ ID NO:1) 3093

FIG.2C

SUBSTITUTE SHEET (RULE 26)

7/14

SILCTGLFKV DPRGEVGAKN LPPSSPRGPE ANLEVRPKES WNHADVFHCE
DTESVPGKPS VNADEEVGGP QICRVCGDKA TGYHENVMTC EGCKGFFERRA
MKRNARLRCP FRKGACEITR KTRROCOACR LKCLESGMK KEMIMSDEAV
EERRALIKRK KSERTGTQPL GVQGLTEEQR MMIRELMDAQ MKTFDITFSH
FKNFRLPGVL SSGCELPESL QAPSREEAAK WSQVRKDLCS LKVSLQLRGE
DGSVWNYKPP ADSSGKEIFS LLPHMADMST YMFKGIISFA KVISYFRDLP
IEDQISLLKG AAFELCOLRF NTVFNAETGT WECGRLSYCL EDTAGGFQQL
LLEPMLKFHY MLKKLQLHEE EYVLMQAISL FSPDRPGVLQ HRVVDQLQEQ
FAITLKSIE CNRPQPAHRF LFLKIMAMLT ELRSINAQHT QRLLRIQDIH
PFATPLMQEL FGITGS (SEQ ID NO:2)

FIG.3

8/14

1 TCCATCCTAA TACGACTCAC TATAGGGCTC GAGCGGCCGC CCGGGCAGGT
51 CTTTTGGCCT GCTGGGTIAG TGCTGGCAGC CCCCTGAGGC CAAGGACAGC
101 AGCATGACAG TCACCAGGAC TCACCACTTC AAGGAGGGGT CCCTCAGAGC
151 ACCTGCCATA CCCCTGCACA GTGCTGCGGC TGAGTTGGCT TCAAACCATC
201 CAAGAGGCCC AGAAGCAAAC CTGGAGGTGA GACCCAAAGA AAGCTGGAAC
251 CATGCTGACT TTGTACACTG TGAGGACACA GAGTCTGTTC CTGGAAAGCC
301 CAGTGTCAAC GCAGATGAGG AAGTCGGAGG TCCCCAAATC TGCCGTGTAT
351 GTGGGGACAA GGCCACTGGC TATCACTTCA ATGTCATGAC ATGTGAAGGA
401 TGCAAGGGCT TTTTCAGGAG GGCCATGAAA CGCAACGCCC GGCTGAGGTG
451 CCCCTTCCGG AAGGGCGCCT GCGAGATCAC CCGGAAGACC CGGCGACAGT
501 GCCAGGCCTG CCGCCTGCGC AAGTGCCTGG AGAGCGGCAT GAAGAAGGAG
551 ATGATCATGT CCGACGAGGC CGTGGAGGAG AGGCGGGCCT TGATCAAGCG
601 GAAGAAAAGT GAACGGACAG GGA CTCAGCC ACTGGGAGTG CAGGGGCTGA
651 CAGAGGAGCA GCGGATGATG ATCAGGGAGC TGATGGACGC TCAGATGAAA
701 ACCTTTGACA CTACCTTCTC CCATTTCAAG AATTTCCGGC TGCCAGGGGT
751 GCTTAGCAGT GGCTGCGAGT TGCCAGAGTC TCTGCAGGCC CCATCGAGGG
801 AAGAAGCTGC CAAGTGGAGC CAGGTCCGGA AAGATCTGTG CTCTTTGAAG
851 GTCTCTCTGC AGCTGCGGGG GGAGGATGGC AGTGTCTGGA ACTACAAACC
901 CCCAGCCGAC AGTGGCGGGA AAGAGATCTT CTCCCTGCTG CCCCACATGG
951 CTGACATGTC AACCTACATG TTCAAAGGCA TCATCAGCTT TGCCAAAGTC
1001 ATCTCCTACT TCAGGGACTT GCCCATCGAG GACCAGATCT CCCTGCTGAA
1051 GGGGGCCGCT TTCGAGCTGT GTCAACTGAG ATTCAACACA GTGTTCAACG

FIG.4A

9/14

1101 CGGAGACTGG AACCTGGGAG TGTGGCCGGC TGTCTACTG CTTGAAGAC
1151 ACTGCAGGTG GCTTCCAGCA ACTTCTACTG GAGCCCATGC TGAAATTCCA
1201 CTACATGCTG AAGAAGCTGC AGCTGCATGA GGAGGAGTAT GTGCTGATGC
1251 AGGCCATCTC CCTCTTCTCC CCAGACCGCC CAGGTGTGCT GCAGCACCGC
1301 GTGGTGGACC AGCTGCAGGA GCAATTCGCC ATTACTCTGA AGTCCTACAT
1351 TGAATGCAAT CGGCCCCAGC CTGCTCATAG GTTCTTGTTT CTGAAGATCA
1401 TGGCTATGCT CACCGAGCTC CGCAGCATCA ATGCTCAGCA CACCCAGCGG
1451 CTGCTGCGCA TCCAGGACAT ACACCCCTTT GCTACGCCCC TCATGCAGGA
1501 GTTGTTCGGC ATCACAGGTA GCTGAGCGGC TGCCCTTGGG TGACACCTCC
1551 GAGAGGCAGC CAGACCCAGA GCCCTCTGAG CCGCCACTCC CGGGCCAAGA
1601 CAGATGGACA CTGCCAAGAG CCGACAATGC CCTGCTGGCC TGTCTCCCTA
1651 GGGAATTCCT GCTATGACAG CTGGCTAGCA TTCCTCAGGA AGGACATGGG
1701 TGCCCCCAC CCCAGTTCA GTCTGTAGGG AGTGAAGCCA CAGATTCTTA
1751 CGTGGAGAGT GCACTGACCT GTAGGTCAGG ACCATCAGAG AGGCAAGGTT
1801 GCCCTTTCCT TTAAAAAGGC CCTGTGGTCT GGGGAGAAAT CCCTCAGATC
1851 CCACTAAAGT GTCAAGGTGT GGAAGGGACC AAGCGACCAA GGATAGGCCA
1901 TCTGGGGTCT ATGCCACAT ACCCACGTTT GTTCGCTTCC TGAGTCTTTT
1951 CATTGCTACC TCTAATAGTC CTGTCTCCA CTTCCCACTC GTTCCCCTCC
2001 TCTTCCGAGC TGCTTTGTGG GCTCCAGGCC TGTACTCATC GGCAGGTGCA
2051 TGAGTATCTG TGGGAGTCCT CTAGAGAGAT GAGAAGCCAG GAGGCCTGCA
2101 CCAAATGTCA GAAGCTTGGC ATGACCTCAT TCCGGCCACA TCATTCTGTG
2151 TCTCTGCATC CATTGAACA CATTATTAAG CACCGATAAT AGGTAGCCTG

FIG.4B

10/14

2201 CTGTGGGGTA TACAGCATTG ACTCAGATAT AGATCCTGAG CTCACAGAGT
2251 TTATAGTTAA AAAACAAAC AGAAACACAA ACAATTTGGA TCAAAAGGAG
2301 AAATGATAAG TGACAAAAGC AGCACAAGGA ATTTCCCTGT GTGGATGCTG
2351 AGCTGTGATG GCGGGCACTG GGTACCCAAG TGAAGGTTCC CGAGGACATG
2401 AGTCTGTAGG AGCAAGGGCA CAAACTGCAG CTGTGAGTGC GTGTGTGTGA
2451 TTTGGTGTAG GTAGGTCTGT TTGCCACTTG ATGGGGCCTG GGTGTGTTCC
2501 TGGGGCTGGA ATGCTGGGTA TGCTCTGTGA CAAGGCTACG CTGACAATCA
2551 GTTAAACACA CCGGAGAAGA ACCATTTACA TGCACCTTAT ATTTCTGTGT
2601 ACACATCTAT TCTCAAAGCT AAAGGGTATG AAAGTGCCTG CCTTGTTTAT
2651 AGCCACTTGT GAGTAAAAAT TTTTTTGCAT TTTCACAAAT TATACTTTAT
2701 ATAAGGCATT CCACACCTAA GAACTAGTTT TGGGAAATGT AGCCCTGGGT
2751 TTAATGTCAA ATCAAGGCAA AAGGAATTAA ATAATGTACT TTTGGCTAGA
2801 GGGGTAAACT TTTTGGCCT TTTTCTGGGG AAAATAATGT GGGGGTGTGG
(SEQ ID NO:17)

FIG.4C

11/14

TCCATCCTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGCAGGTCTTTTGGCCT 60
GCTGGGTTAGTGCTGGCAGCCCCCTGAGGCCAAGGACAGCAGCATGACAGTCACCAGGAC 120
TCACCACTTCAAGGAGGGGTCCCTCAGAGCACCTGCCATACCCCTGCACAGTGCTGCGGC 180
H H F K E G S L R A P A I P L H S A A A
TGAGTTGGCTTCAAACCATCCAAGAGGCCAGAAGCAAACCTGGAGGTGAGACCCAAAGA 240
E L A S N H P R G P E A N L E V R P K E
AAGCTGGAACCATGCTGACTTTGTACACTGTGAGGACACAGAGTCTGTTCTGGAAGCC 300
S W N H A D F V H C E D T E S V P G K P
CAGTGTC AACGCAGATGAGGAAGTCGGAGGTCCCCAAATCTGCCGTGTATGTGGGGACAA 360
S V N A D E E V G G P Q I C R V C G D K
GGCCACTGGCTATCACTTCAATGTCATGACATGTGAAGGATGCAAGGGCTTTTTCAGGAG 420
A T G Y H F N V M T C E G C K G F F R R
GGCCATGAAACGCAACGCCGGCTGAGGTGCCCTTCCGGAAGGGCGCCTGCGAGATCAC 480
A M K R N A R L R C P F R K G A C E I T
CCGGAAGACCCGGCGACAGTGCCAGGCCTGCCGCTGCGCAAGTGCCTGGAGAGCGGCAT 540
R K T R R Q C Q A C R L R K C L E S G M
GAAGAAGGAGATGATCATGTCCGACGAGGCCGTGGAGGAGAGGGCGGCCTTGATCAAGCG 600
K K E M I M S D E A V E E R R A L I K R
GAAGAAAAGTGAACGGACAGGACTCAGCCACTGGGAGTGCAGGGGCTGACAGAGGAGCA 660
K K S E R T G T Q P L G V Q G L T E E Q
GCGGATGATGATCAGGGAGCTGATGGACGCTCAGATGAAAACCTTTGACACTACCTTCTC 720
R M M I R E L M D A Q M K T F D T T F S
CCATTTCAAGAATTTCCGGCTGCCAGGGGTGCTTAGCAGTGGCTGCGAGTTGCCAGAGTC 780
H F K N F R L P G V L S S G C E L P E S
TCTGCAGGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGCCAGGTCCGGAAGATCTGTG 840
L Q A P S R E E A A K W S Q V R K D L C
CTCTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGCAGTGTCTGGAAC TACAAACC 900
S L K V S L Q L R G E D G S V W N Y K P
CCCAGCCGACAGTGGCGGGAAAGAGATCTTCTCCCTGCTGCCCCACATGGCTGACATGTC 960
P A D S G G K E I F S L L P H M A D M S
AACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTCATCTCCTACTTCAGGGACTT 1020
T Y M F K G I I S F A K V I S Y F R D L

FIG.5A

12/14

GCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGCCGCTTTCGAGCTGTGTCAACTGAG 1080
P I E D Q I S L L K G A A F E L C Q L R

ATTCAACACAGTGTTC AACGCGGAGACTGGAACCTGGGAGTGTGGCCGGCTGTCTACTG 1140
F N T V F N A E T G T W E C G R L S Y C

CTTGGAAGACACTGCAGGTGGCTTCCAGCAACTTCTACTGGAGCCCATGCTGAAATTCCA 1200
L E D T A G G F Q Q L L L E P M L K F H

CTACATGCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTATGTGCTGATGCAGGCCATCTC 1260
Y M L K K L Q L H E E E Y V L M Q A I S

CCTCTTCTCCCCAGACCGCCAGGTGTGCTGCAGCACCGCGTGGTGGACCAGCTGCAGGA 1320
L F S P D R P G V L Q H R V V D Q L Q E

GCAATTCGCCATTACTCTGAAGTCCTACATTGAATGCAATCGGCCCCAGCCTGCTCATAG 1380
Q F A I T L K S Y I E C N R P Q P A H R

GTTCTTGTTCTCTGAAGATCATGGCTATGCTCACCGAGCTCCGCAGCATCAATGCTCAGCA 1440
F L F L K I M A M L T E L R S I N A Q H

CACCCAGCGGGTCTGCGCATCCAGGACATACACCCCTTTGCTACGCCCTCATGCAGGA 1500
T Q R L L R I Q D I H P F A T P L M Q E

GTTGTTCCGGCATCACAGGTAGCTGAGCGGCTGCCCTTGGGTGACACCTCCGAGAGGCAGC 1560
L F G I T G S (SEQ ID NO:18)

CAGACCCAGAGCCCTCTGAGCCGCCACTCCCGGGCCAAGACAGATGGACACTGCCAAGAG 1620

CCGACAATGCCCTGCTGGCCTGTCTCCCTAGGAATTCCTGCTATGACAGCTGGCTAGCA 1680

TTCCTCAGGAAGGACATGGGTGCCCCCACCCTCAGTTCAGTCTGTAGGGAGTGAAGCCA 1740

CAGATTCTTACGTGGAGAGTGCACTGACCTGTAGGTCAGGACCATCAGAGAGGCAAGGTT 1800

GCCCTTTCCTTTTAAAAGGCCCTGTGGTCTGGGGAGAAATCCCTCAGATCCCACTAAAGT 1860

GTCAAGGTGTGGAAGGGACCAAGCGACCAAGGATAGGCCATCTGGGGTCTATGCCACAT 1920

ACCCACGTTTGTTCGCTTCCTGAGTCTTTTCATTGCTACCTCTAATAGTCTGTCTCCA 1980

CTTCCCACTCGTTCCCTCCTCTTCCGAGCTGCTTTGTGGGCTCCAGGCCTGTACTCATC 2040

GGCAGGTGCATGAGTATCTGTGGGAGTCTCTAGAGAGATGAGAAGCCAGGAGGCCTGCA 2100

CCAAATGTCAGAAGCTTGGCATGACCTCATTCCGGCCACATCATTCTGTGTCTCTGCATC 2160

CATTTGAACACATTATTAAGCACCGATAATAGGTAGCCTGCTGTGGGGTATACAGCATTG 2220

FIG.5B

13/14

ACTCAGATATAGATCCTGAGCTCACAGAGTTTATAGTTAAAAAACAAACAGAAACACAA 2280
ACAATTTGGATCAAAAGGAGAAATGATAAGTGACAAAAGCAGCACAAGGAATTTCCCTGT 2340
GTGGATGCTGAGCTGTGATGGCGGGCACTGGGTACCCAAGTGAAGGTTCCCGAGGACATG 2400
AGTCTGTAGGAGCAAGGGCACAACTGCAGCTGTGAGTGCGTGTGTGTGATTTGGTGTAG 2460
GTAGGTCTGTTTGCCACTTGATGGGGCCTGGGTTTGTTCCTGGGGCTGGAATGCTGGGTA 2520
TGCTCTGTGACAAGGCTACGCTGACAATCAGTTAAACACACCGGAGAAGAACCATTTACA 2580
TGCACCTTATATTTCTGTGTACACATCTATTCTCAAAGCTAAAGGTATGAAAGTGCCTG 2640
CCTTGTTTATAGCCACTTGTGAGTAAAAATTTTTTGCATTTTCACAAATTATACTTTAT 2700
ATAAGGCATTCCACACCTAAGAACTAGTTTTGGGAAATGTAGCCCTGGGTTTAATGTCAA 2760
ATCAAGGCAAAAGGAATTAAATAATGTACTTTTGGCTAGAGGGGTAACTTTTTTGGCCT 2820
TTTTCTGGGGAAAATAATGTGGGGGTGTGG (SEQ ID NO:17) 2850

FIG.5C

14/14

1 MTVTRTHHEK EGSLRAPAIP LHSAAELAS NHPRGPEANL EVRPKESWNH
51 ADFVHCEDTE SVPGKPSVNA DEEVGGPQIC RVC GDKATGY HFN VMTCEGC
101 KGFFRRAMKR NARLRCPFRK GACEITRKTR RQCQACRLRK CLESGMKKEM
151 IMSDEAVEER RALIKRKKSE RTGTQPLGVQ GLTEEQRMMI RELMDAQMKT
201 FDTTFSHFKN FRLPGVLSSG CELPESLQAP SREEAAKWSQ VRKDLC SLKV
251 SLQLRGEDGS VWNYPKPPADS GGKEIFSLLP HMADMSTYMF KGIISFAKVI
301 SYFRDLPIED QISLLKGA AF ELCQLRFNTV FNAETGTWEC GRLSYCLEDT
351 AGGFQQLLLE PMLKFHYMLK KLQLHEEEYV LMQAISLFSP DRPGVLQHRV
901 VDQLQE QFAI TLKSYIECNR PQPAHRFLFL KIMAMLTELR SINAQHTQRL
451 LRIQDIHPFA TPLMQELFGI TGS (SEQ ID NO:18)

FIG.6

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> DNA MOLECULES ENCODING HUMAN NUCLEAR
RECEPTOR PROTEINS, nNR-7 AND nNR7-1

<130> 20084Y PCT

<160> 24

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 3093

<212> DNA

<213> Homo sapien (human)

<400> 1

tacgccaaagc	tcgaaattaa	ccctcactaa	agggaaacaaa	agctggagct	ccaccgcggt	60
ggcgcccgct	ctagaactag	tggatcccc	gggetgcagg	aattcgaatt	ctcataacct	120
atgactagga	cggaagagg	aagcactgcc	tttacttcag	tgggaatctc	ggcctcagcc	180
tgcaagccaa	gtgttcacag	tgagaaaagc	aagagaataa	gctaatactc	ctgtcctgaa	240
caaggcagcg	gctccttgg	aaagctactc	cttgatcgat	cctttgcacc	ggattgttca	300
aagtggaccc	caggggagaa	gtcggagcaa	agaacttacc	accaagcagt	ccaagaggcc	360
cagaagcaaa	cctggaggtg	agacccaaag	aaagctggaa	ccatgctgac	ttgtacact	420
gtgaggacac	agagtctgtt	cctggaaaagc	ccagtgtcaa	cgcagatgag	gaagtgggag	480
gtccccaaat	ctgccgtgta	tgtggggaca	aggccactgg	ctatcacttc	aatgtcatga	540
catgtgaagg	atgcaagggc	tttttcagga	gggccatgaa	acgcaacgcc	cggctgaggt	600
gcccccttcg	gaagggcgcc	tgcgagatca	cccggaagac	ccggcgacag	tgccaggcct	660
gccgcctgcg	caagtgcctg	gagagcggca	tgaagaagga	gatgatcatg	tccgacgagg	720
ccgtggagga	gagggcgggc	ttgatcaagc	ggaagaaaag	tgaacggaca	gggactcagc	780
cactgggagt	gcaggggctg	acagaggagc	agcggatgat	gatcagggag	ctgatggacg	840
ctcagatgaa	aacctttgac	actaccttct	cccatttcaa	gaatttccgg	ctgccagggg	900
tgcttagcag	tggtgcgag	ttgccagagt	ctctgcaggc	cccatcgagg	gaagaagctg	960
ccaagtggag	ccaggtccgg	aaagatctgt	gctctttgaa	ggtctctctg	cagctgcggg	1020
gggaggatgg	cagtgtcttg	aactacaaac	ccccagccga	cagtggcggg	aaagagatct	1080
tctccctgct	gccccacatg	gctgacatgt	caacctacat	gttcaaaggc	atcatcagct	1140
ttgccaaaagt	catctcctac	ttcagggact	tgcccatcga	ggaccagatc	tccctgctga	1200
agggggcgcg	tttcgagctg	tgtcaactga	gattcaacac	agtgttcaac	gcggagactg	1260
gaacctggga	gtgtggccgg	ctgtcctact	gcttggaaga	cactgcaggt	ggcttcagc	1320
aacttctact	ggagcccatg	ctgaaattcc	actacatgct	gaagaagctg	cagctgcatg	1380
aggaggagta	tgtgctgatg	caggccatct	ccctcttctc	cccagaccgc	ccaggtgtgc	1440
tgcagcaccg	cgtgggtggc	cagctgcagg	agcaattcgc	cattactctg	aagtccctaca	1500
ttgaatggcaa	tcggccccag	cctgctcata	ggttcttggt	cctgaagatc	atggctatgc	1560
tcaccgagct	ccgcagcatc	aatgctcagc	acaccagcgg	gctgctgcgc	atccaggaca	1620
tacacccctt	tgctacgccc	ctcatgcagg	agttgttcgg	catcacaggt	agctgagcgg	1680
ctgcccttgg	gtgacacctc	cgagaggcag	ccagacccag	agccctctga	gccgccactc	1740
ccgggccaag	acagatggac	actgccaaga	gccgacaatg	ccctgctggc	ctgtctccct	1800
agggaaattc	tgctatgaca	gctggctagc	attctctagg	aaggacatgg	gtgcccccca	1860
ccccagttc	agtctgtagg	gagtgaagcc	acagattctt	acgtggagag	tgcactgacc	1920
tgtaggtcag	gaccatcaga	gaggcaaggt	tgccttttcc	ttttaaaagg	ccctgtggtc	1980
tggggagaaa	tcctcagat	cccactaaag	tgtcaagggt	tggaaaggac	caagcgacca	2040
aggataggcc	atctggggtc	tatgccaca	tacccacgtt	tgttcgcttc	ctgagtcctt	2100
tcattgctac	ctctaatagt	cctgtctccc	acttcccact	cgttcccctc	ctcttcagag	2160

```

ctgctttgtg ggctccaggc ctgtactcat cggcaggtgc atgagtatct gtgggagtc 2220
tctagagaga tgagaagcca ggaggcctgc accaaatgtc agaagcttgg catgacctca 2280
ttccggccac atcattctgt gtctctgcat ccatttgaac acattattaa gcaccgataa 2340
taggtagcct gctgtggggg atacagcatt gactcagata tagatcctga gctcacagag 2400
tttatagtta aaaaaacaaa cagaaacaca aacaatttgg atcaaaagga gaaatgataa 2460
gtgacaaaag cagcacaagg aatttccttg tgtggatgct gagctgtgat ggcggggcact 2520
gggtacccaa gtgaagggtc cggaggacat gagtctgtag gagcaagggc acaaactgca 2580
gctgtgagtg cgtgtgtgtg atttggtgta ggtaggtctg tttgccactt gatggggcct 2640
gggtttgttc ctggggctgg aatgctgggt atgctctgtg acaaggctac gctgacaatc 2700
agttaaacac accggagaag aaccatttac atgcacctta tatttctgtg tacacatcta 2760
ttctcaaagc taaagggtat gaaagtgcct gccttgttta tagccacttg tgagtaaaaa 2820
tttttttgca ttttcacaaa ttatacttta tataaggcat tccacaccta agaactagtt 2880
ttgggaaatg tagccctggg tttaatgtca aatcaaggca aaaggaatta aataatgtac 2940
ttttgctag aggggtaaac ttttttggcc tttttctggg gaaaataatg tgggggtgtg 3000
ggaattcgaa ttcgatatca agcttatcga taccgtcgac ctcgaggggg ggcccggtag 3060
ccaattcgcc ctatagttag tcgtattaca att 3093

```

<210> 2

<211> 466

<212> PRT

<213> Homo sapien (human)

<400> 2

```

Ser Ile Leu Cys Thr Gly Leu Phe Lys Val Asp Pro Arg Gly Glu Val
1           5           10           15
Gly Ala Lys Asn Leu Pro Pro Ser Ser Pro Arg Gly Pro Glu Ala Asn
20           25           30
Leu Glu Val Arg Pro Lys Glu Ser Trp Asn His Ala Asp Phe Val His
35           40           45
Cys Glu Asp Thr Glu Ser Val Pro Gly Lys Pro Ser Val Asn Ala Asp
50           55           60
Glu Glu Val Gly Gly Pro Gln Ile Cys Arg Val Cys Gly Asp Lys Ala
65           70           75           80
Thr Gly Tyr His Phe Asn Val Met Thr Cys Glu Gly Cys Lys Gly Phe
85           90           95
Phe Arg Arg Ala Met Lys Arg Asn Ala Arg Leu Arg Cys Pro Phe Arg
100          105          110
Lys Gly Ala Cys Glu Ile Thr Arg Lys Thr Arg Arg Gln Cys Gln Ala
115          120          125
Cys Arg Leu Arg Lys Cys Leu Glu Ser Gly Met Lys Lys Glu Met Ile
130          135          140
Met Ser Asp Glu Ala Val Glu Glu Arg Arg Ala Leu Ile Lys Arg Lys
145          150          155          160
Lys Ser Glu Arg Thr Gly Thr Gln Pro Leu Gly Val Gln Gly Leu Thr
165          170          175
Glu Glu Gln Arg Met Met Ile Arg Glu Leu Met Asp Ala Gln Met Lys
180          185          190
Thr Phe Asp Thr Thr Phe Ser His Phe Lys Asn Phe Arg Leu Pro Gly
195          200          205
Val Leu Ser Ser Gly Cys Glu Leu Pro Glu Ser Leu Gln Ala Pro Ser
210          215          220
Arg Glu Glu Ala Ala Lys Trp Ser Gln Val Arg Lys Asp Leu Cys Ser
225          230          235          240
Leu Lys Val Ser Leu Gln Leu Arg Gly Glu Asp Gly Ser Val Trp Asn
245          250          255

```

Tyr Lys Pro Pro Ala Asp Ser Gly Gly Lys Glu Ile Phe Ser Leu Leu
 260 265 270
 Pro His Met Ala Asp Met Ser Thr Tyr Met Phe Lys Gly Ile Ile Ser
 275 280 285
 Phe Ala Lys Val Ile Ser Tyr Phe Arg Asp Leu Pro Ile Glu Asp Gln
 290 295 300
 Ile Ser Leu Leu Lys Gly Ala Ala Phe Glu Leu Cys Gln Leu Arg Phe
 305 310 315 320
 Asn Thr Val Phe Asn Ala Glu Thr Gly Thr Trp Glu Cys Gly Arg Leu
 325 330 335
 Ser Tyr Cys Leu Glu Asp Thr Ala Gly Gly Phe Gln Gln Leu Leu Leu
 340 345 350
 Glu Pro Met Leu Lys Phe His Tyr Met Leu Lys Lys Leu Gln Leu His
 355 360 365
 Glu Glu Glu Tyr Val Leu Met Gln Ala Ile Ser Leu Phe Ser Pro Asp
 370 375 380
 Arg Pro Gly Val Leu Gln His Arg Val Val Asp Gln Leu Gln Glu Gln
 385 390 395 400
 Phe Ala Ile Thr Leu Lys Ser Tyr Ile Glu Cys Asn Arg Pro Gln Pro
 405 410 415
 Ala His Arg Phe Leu Phe Leu Lys Ile Met Ala Met Leu Thr Glu Leu
 420 425 430
 Arg Ser Ile Asn Ala Gln His Thr Gln Arg Leu Leu Arg Ile Gln Asp
 435 440 445
 Ile His Pro Phe Ala Thr Pro Leu Met Gln Glu Leu Phe Gly Ile Thr
 450 455 460
 Gly Ser
 465

<210> 3
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide

<400> 3
 cttcaatgtc atgacatg

18

<210> 4
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide

<400> 4
 ccaaactctgc cgtgtatgtg

20

<210> 5
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 5
gtcagtgcac tctccacgt 19

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 6
tgcagctggt ccaccacgcg 20

<210> 7
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 7
gggtatgctc tgtgacaag 19

<210> 8
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 8
aggcaggcac tttcatacc 19

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 9
tttcgagctt ccagggtcat 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 10
ctcccaaact ctgcttggtg 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 11
cgggagccac acttcacat 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 12
gttcacttct gcgctgtctg 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 13
ttccgggctc ccagagtcac 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 14
cagaagacct gcctgatctg 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 15
 gaaatgaact ccttcatcat 20

<210> 16
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide

<400> 16
 ccggatctgt ggggtgtgtg 20

<210> 17
 <211> 2850
 <212> DNA
 <213> Homo sapien (human)

<400> 17

tccatcctaa	tacgaactcac	tatagggctc	gagcgccgc	ccgggcaggt	cttttggcct	60
gctgggttag	tgctggcagc	cccctgaggc	caaggacagc	agcatgacag	tcaccaggac	120
tcaccacttc	aaggaggggt	ccctcagagc	acctgccata	cccctgcaca	gtgetgcggc	180
tgagttggct	tcaaaccatc	caagaggccc	agaagcaaac	ctggaggtga	gacccaaaga	240
aagctggaac	catgctgact	ttgtacactg	tgaggacaca	gagtctgttc	ctggaaagcc	300
cagtgccaac	gcagatgagg	aagtcggagg	tccccaatc	tgccgtgtat	gtggggacaa	360
ggccactggc	tatcacttca	atgtcatgac	atgtgaagga	tgcaagggt	ttttcaggag	420
ggccatgaaa	cgcaacgccc	ggctgaggtg	ccccttccgg	aaggcgccct	gcgagatcac	480
ccggaagacc	cggcgacagt	gccaggcctg	ccgctcgcc	aagtgcctgg	agagcggcat	540
gaagaaggag	atgatcatgt	ccgacgaggc	cgtggaggag	aggcgggcct	tgatcaagcg	600
gaagaaaagt	gaacggacag	ggactcagcc	actgggagtg	caggggctga	cagaggagca	660
gcggtatgat	atcagggagc	tgatggacgc	tcagatgaaa	acctttgaca	ctaccttctc	720
ccatttcaag	aatttccggc	tgccaggggt	gcttagcagt	ggctgcgagt	tgccagagtc	780
tctgcaggcc	ccatcgaggg	aagaagctgc	caagtggagc	caggtccgga	aagatctgtg	840
ctctttgaag	gtctctctgc	agctgcgggg	ggaggatggc	agtgtctgga	actacaaacc	900
cccagccgac	agtggcggga	aagagatctt	ctccctgctg	ccccacatgg	ctgacatgtc	960
aacctacatg	ttcaaaggca	tcatacagct	tgccaaagtc	atctcctact	tcagggaactt	1020
gccccatcag	gaccagatct	ccctgctgaa	gggggcccgt	ttcgagctgt	gtcaactgag	1080
attcaacaca	gtgttcaacg	cggagactgg	aacctgggag	tgtggccggc	tgctcctactg	1140
cttgggaagac	actgcaggtg	gcttccagca	acttctactg	gagcccatgc	tgaaattcca	1200
ctacatgctg	aagaagctgc	agctgcatga	ggaggagtat	gtgctgatgc	aggccatctc	1260
cctcttctcc	ccagaccgcc	caggtgtgct	gcagcaccgc	gtggtggacc	agctgcagga	1320
gcaattctgc	attactctga	agtcctacat	tgaatgcaat	cggccccagc	ctgctcatag	1380
gttcttgttc	ctgaagatca	tggtatgct	caccgagctc	cgcagcatca	atgctcagca	1440
cacccagcgg	ctgctgcgca	tccaggacat	acaccccttt	gctacgcccc	tcatgcagga	1500
gttgttcggc	atcacaggta	gctgagcggc	tgcccttggg	tgacacctcc	gagaggcagc	1560
cagacccaga	gcccctctgag	ccgccactcc	cgggccaaaga	cagatggaca	ctgccaagag	1620
ccgacaatgc	cctgctggcc	tgtctcccta	gggaattcct	gctatgacag	ctggctagca	1680
ttcctcagga	aggacatggg	tgccccccac	ccccagttca	gtctgtaggg	agtgaagcca	1740
cagattctta	cgtggagagt	gcaactgacct	gtaggtcagg	accatcagag	aggcaagggtt	1800
gccccttccct	tttaaaaggc	cctgtggtct	ggggagaaat	ccctcagatc	ccactaaagt	1860
gtcaagggtgt	ggaagggaacc	aagcgaccaa	ggataggcca	tctggggtct	atgcccacat	1920
acccacgttt	gttcgcttcc	tgagtctttt	cattgctacc	tctaatagtc	ctgtctccca	1980
cttcccactc	gttcccctcc	tcttccgagc	tgctttgtgg	gctccaggcc	tgtactcatc	2040
ggcaggtgca	tgagtatctg	tgggagtcct	ctagagagat	gagaagccag	gaggcctgca	2100

```

ccaaatgtca gaagcttggc atgacctcat tccggccaca tcattctgtg tctctgcatc 2160
catttgaaca cattattaag caccgataat aggtagcctg ctgtggggta tacagcattg 2220
actcagatat agatcctgag ctcacagagt ttatagttaa aaaaacaaac agaaacacaa 2280
acaatttggg tcaaaaggag aaatgataag tgacaaaagc agcacaagga atttcctgt 2340
gtggatgctg agctgtgatg gcgggcaact ggtacccaag tgaagggtcc cgaggacatg 2400
agtctgtagg agcaagggca caaactgcag ctgtgagtgc gtgtgtgtga tttggtgtag 2460
gtaggtctgt ttgccacttg atggggcctg ggtttgttcc tggggctgga atgctgggta 2520
tgctctgtga caaggctacg ctgacaatca gttaaacaca ccggagaaga accattttaca 2580
tgcaccttat atttctgtgt acacatctat tctcaaagct aaagggtatg aaagtgcctg 2640
ccttgtttat agccacttgt gagtaaaaat ttttttgcac tttcacaaat tatactttat 2700
ataaggcatt ccacacctaa gaactagttt tgggaaatgt agccctgggt ttaatgtcaa 2760
atcaaggcaa aaggaattaa ataatgtact tttggctaga ggggtaaact tttttggcct 2820
ttttctgggg aaaataatgt ggggggtgtg

```

<210> 18
 <211> 473
 <212> PRT
 <213> Homo sapien (human)

```

<400> 18
Met Thr Val Thr Arg Thr His His Phe Lys Glu Gly Ser Leu Arg Ala
1 5 10 15
Pro Ala Ile Pro Leu His Ser Ala Ala Ala Glu Leu Ala Ser Asn His
20 25 30
Pro Arg Gly Pro Glu Ala Asn Leu Glu Val Arg Pro Lys Glu Ser Trp
35 40 45
Asn His Ala Asp Phe Val His Cys Glu Asp Thr Glu Ser Val Pro Gly
50 55 60
Lys Pro Ser Val Asn Ala Asp Glu Glu Val Gly Gly Pro Gln Ile Cys
65 70 75 80
Arg Val Cys Gly Asp Lys Ala Thr Gly Tyr His Phe Asn Val Met Thr
85 90 95
Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ala Met Lys Arg Asn Ala
100 105 110
Arg Leu Arg Cys Pro Phe Arg Lys Gly Ala Cys Glu Ile Thr Arg Lys
115 120 125
Thr Arg Arg Gln Cys Gln Ala Cys Arg Leu Arg Lys Cys Leu Glu Ser
130 135 140
Gly Met Lys Lys Glu Met Ile Met Ser Asp Glu Ala Val Glu Glu Arg
145 150 155 160
Arg Ala Leu Ile Lys Arg Lys Lys Ser Glu Arg Thr Gly Thr Gln Pro
165 170 175
Leu Gly Val Gln Gly Leu Thr Glu Glu Gln Arg Met Met Ile Arg Glu
180 185 190
Leu Met Asp Ala Gln Met Lys Thr Phe Asp Thr Thr Phe Ser His Phe
195 200 205
Lys Asn Phe Arg Leu Pro Gly Val Leu Ser Ser Gly Cys Glu Leu Pro
210 215 220
Glu Ser Leu Gln Ala Pro Ser Arg Glu Glu Ala Ala Lys Trp Ser Gln
225 230 235 240
Val Arg Lys Asp Leu Cys Ser Leu Lys Val Ser Leu Gln Leu Arg Gly
245 250 255
Glu Asp Gly Ser Val Trp Asn Tyr Lys Pro Pro Ala Asp Ser Gly Gly
260 265 270
Lys Glu Ile Phe Ser Leu Leu Pro His Met Ala Asp Met Ser Thr Tyr
275 280 285

```

Met Phe Lys Gly Ile Ile Ser Phe Ala Lys Val Ile Ser Tyr Phe Arg
 290 295 300
 Asp Leu Pro Ile Glu Asp Gln Ile Ser Leu Leu Lys Gly Ala Ala Phe
 305 310 315 320
 Glu Leu Cys Gln Leu Arg Phe Asn Thr Val Phe Asn Ala Glu Thr Gly
 325 330 335
 Thr Trp Glu Cys Gly Arg Leu Ser Tyr Cys Leu Glu Asp Thr Ala Gly
 340 345 350
 Gly Phe Gln Gln Leu Leu Leu Glu Pro Met Leu Lys Phe His Tyr Met
 355 360 365
 Leu Lys Lys Leu Gln Leu His Glu Glu Glu Tyr Val Leu Met Gln Ala
 370 375 380
 Ile Ser Leu Phe Ser Pro Asp Arg Pro Gly Val Leu Gln His Arg Val
 385 390 395 400
 Val Asp Gln Leu Gln Glu Gln Phe Ala Ile Thr Leu Lys Ser Tyr Ile
 405 410 415
 Glu Cys Asn Arg Pro Gln Pro Ala His Arg Phe Leu Phe Leu Lys Ile
 420 425 430
 Met Ala Met Leu Thr Glu Leu Arg Ser Ile Asn Ala Gln His Thr Gln
 435 440 445
 Arg Leu Leu Arg Ile Gln Asp Ile His Pro Phe Ala Thr Pro Leu Met
 450 455 460
 Gln Glu Leu Phe Gly Ile Thr Gly Ser
 465 470

<210> 19
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide

<400> 19
 aagcccttgcc atccttcaca

20

<210> 20
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide

<400> 20
 ccatacctaatacgcact atagggc

27

<210> 21
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide

<400> 21
gtaccgagct cggatccact a 21

<210> 22
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 22
ccgccagtgt gatggatatt t 21

<210> 23
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 23
ctcatctgcg ttgacactgg g 21

<210> 24
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 24
tgaactcaaa ggaggtca 18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26364

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/00, 14/705; C12N 5/16, 15/12, 15/63; G01N 33/53, 33/566

US CL : 435/7.1, 69.1, 320.1, 325; 530/350; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.1, 69.1, 320.1, 325; 530/350; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P ----- A, P	BERTILSSON et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U.S.A. 13 October 1998, Vol. 95, No. 21, pages 12208-12213, see especially figures 1-5.	1-8, 16-27, 35-38 ----- 9-15, 28-34,



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

B earlier document published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A

document member of the same patent family

Date of the actual completion of the international search

15 MARCH 1999

Date of mailing of the international search report

31 MAR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL D. PAK

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/26364

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN, BIOSCIENCE, MEDLINE, CAPLUS, BIOSIS, GENBANK, PIR, EST

search terms: nuclear receptor, nNR7, PPAR, steroid receptor, thyroid receptor